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There is significant evidence that, in living systems, free radicals and other reactive oxygen and nitrogen species play a double
role, because they can cause oxidative damage and tissue dysfunction and serve as molecular signals activating stress responses
that are beneficial to the organism. Mitochondria have been thought to both play a major role in tissue oxidative damage and
dysfunction and provide protection against excessive tissue dysfunction through several mechanisms, including stimulation of
opening of permeability transition pores. Until recently, the functional significance of ROS sources different from mitochondria
has received lesser attention. However, the most recent data, besides confirming the mitochondrial role in tissue oxidative stress and
protection, show interplay between mitochondria and other ROS cellular sources, so that activation of one can lead to activation of
other sources. Thus, it is currently accepted that in various conditions all cellular sources of ROS provide significant contribution
to processes that oxidatively damage tissues and assure their survival, through mechanisms such as autophagy and apoptosis.

1. Introduction
The existence of free radicals, known in chemistry since the
beginning of the 20th century [1], was discovered in biological
systems in 1954 [2]. In the same year, Gerschman et al.
proposed that the noxious effects of hyperbaric oxygen and X
irradiation had a common mechanism which involved radical
and nonradical species, resulting from partial reduction of
oxygen [3]. Soon after, Harman suggested that these species,
at present referred to as reactive oxygen species (ROS), might
play a role in the aging process [4].
Progress in the free radical knowledge occurred in 1969
when the enzyme superoxide dismutase (SOD) was isolated
[5]. The SOD discovery inspired a large number of studies,
which contributed to the knowledge of the ROS, even though
for several decades they were thought to cause exclusively
damaging effects. This view was mainly supported by the
finding that ROS readily react with most biological macromolecules, causing their oxidative modification, ultimately

resulting in the loss of their function [6]. Actually, ROS
include species, such as the hydroxyl radical (∙ OH), whose
reactivity is so high that it reacts very close to its site of
formation [7], and other species, such as superoxide (O2 ∙− )
and hydrogen peroxide (H2 O2 ), which are less reactive
(Table 1). Thus, nitrogen containing species, which are now
indicated as reactive nitrogen species (RNS), include nitric
oxide (NO∙ ), which is relatively unreactive, and its derivative
the peroxynitrite (ONOO− ), a powerful oxidant, able to
damage many biological molecules [8].
Nonetheless, ROS were considered as one of the key
players in tissue injury, if occurring in organisms with a
system of biochemical defenses to neutralize the oxidative
effects of ROS [9], but the balance between ROS generation
and antioxidant system activity is slightly tipped in favor of
the ROS so that, in living systems, there is a continuous low
level of oxidative damage. Moreover, when a greater imbalance occurs in favor of the ROS, oxidative stress ensues [10].
Oxidative stress is a phenomenon which was related to the

2

Oxidative Medicine and Cellular Longevity

Table 1: Main reactive oxygen (ROS) and nitrogen (RNS) species.
∙−

Radicals

Nonradicals

O2
∙
OH
NO∙
NO2 ∙
H2 O2
HOCl
ONOO−

Superoxide anion
Hydroxyl
Nitric oxide
Nitrogen dioxide
Hydrogen peroxide
Hypochlorous acid
Peroxynitrite

development of many pathological conditions. Pathologies
where ROS were identified as causal factors include cardiovascular disease, diabetes, rheumatoid arthritis, cancer, and
neurodegenerative disorders [11] and the use of exogenous
antioxidants was proposed for their treatment [12].
The finding that ∙ OH radical stimulated formation of
cyclic guanosine monophosphate (cGMP) [13] led to an
opposing view about the ROS role in biological systems. Since
then, it became clear that living systems not only adapted to a
coexistence with free radicals but also developed methods to
turn these toxicants to their own advantage utilizing them in
critical physiological processes. This view has been supported
by the observation that, at the cellular level, ROS regulate
growth, apoptosis, and other signaling, while, at the system
level, they contribute to complex functions, including blood
pressure regulation, cognitive function, and immune function [14]. It has also been shown that whereas accumulation
of oxidative damage results in organism death [15], several
longevity-promoting interventions increase generation of
ROS that activate stress responses that are beneficial to the
organism and extend lifespan [16].
Like ROS, RNS play a dual role since they can be either
harmful or beneficial to living systems. Nitric oxide, early
identified as a signaling molecule in blood vessel modulation
[17] and now known as a regulator of important physiological processes [18], can mediate cellular toxicity damaging
metabolic enzymes and generating, by reaction with superoxide, peroxynitrite [19].
Although the role of ROS and RNS in cellular damage and
signal transduction is well-established, several controversial
questions remain open. At low concentrations, ROS and RNS
play an important role as regulatory mediators in signaling
processes, whereas, at moderate or high concentrations,
they are harmful for living organisms inactivating important
cellular molecules. This suggests that the concentrations of
reactive species determine the shift from their advantageous
to detrimental effects, but the concentrations to which this
shift happens are not generally known. Moreover, given the
wide range of possible targets and the general reactivity of
cellular oxidants, it is unclear how any specificity in their
opposite actions can be achieved. It has been suggested
that contributing factors may include cell type, duration
of oxidant production, reactive species produced, and the
localization of their source and their targets [20], but our
information about such a matter is still scarce and discordant.
For example, it has often been assumed that mitochondria
are the main cellular source of ROS in physiological and

pathological conditions [21], so that these organelles have
been thought to play a crucial role in several human diseases
and aging [22]. However, in the light of available data it
seems that evidence that mitochondria are the main source of
cellular ROS is lacking [23]. The issue is complicated by the
existence of a strong interaction among the various sources
of ROS generation in the cell [24, 25], which makes it difficult
to establish what source of reactive species plays a main role
in different physiological and pathological conditions.
To contribute to the understanding of the role of reactive
species sources in health and disease, the present review, after
examining the cellular localization and supposed involvement of such sources in tissue dysfunction and protection,
examines experimental evidence concerning their harmful
and protective effects on a normal physiological activity, such
as exercise, and on pathologic conditions, such as diabetes
and neurodegenerative diseases.

2. Cellular ROS and RNS Sources
In the living organisms, ROS are generated in several cellular
systems localized on the plasma membrane, in the cytosol,
in the peroxisomes, and on membranes of mitochondria and
endoplasmic reticulum (Figure 1).
2.1. ROS Production in the Cytosol. Several soluble cell components, including thiols, hydroquinones, catecholamines,
and flavins, can contribute to intracellular ROS production
as they are able to undergo redox reactions [26]. Moreover,
several cytosolic enzymes produce ROS during their catalytic
activity. Probably the most studied ROS producing enzyme
is xanthine oxidase (XO). In healthy tissues, the enzyme
catalyzing oxidation of hypoxanthine to xanthine and xanthine to uric acid is xanthine dehydrogenase (XDH), which
uses NADP+ as an electron acceptor. Conversely, in damaged
tissues, by either reversible oxidation of cysteine residues
or irreversible Ca2+ -stimulated proteolysis, the enzyme is
converted from the dehydrogenase form into the oxidase
form, which transfers electrons to molecular oxygen producing the superoxide radical during xanthine or hypoxanthine
oxidation [27].
2.2. ROS Production by Mitochondria. In aerobic cells, mitochondria are necessary for numerous fundamental functions,
including respiration and oxidative energy production, regulation of the intracellular calcium concentration, and control
of the fatty acid 𝛽-oxidation.
For a long time, mitochondria have only been considered
for their role in energy production. They utilize about 95% of
the oxygen assumed from aerobic animals to obtain energy
by oxidizing substances contained in food by transfer of
electrons to electron carriers such as NAD+ , FMN, and
FAD. The reduced forms of these molecules, in turn, transfer
electrons to the components of the respiratory chain and
finally to oxygen in a process which happens in a series of
subsequent steps, so that the energy, resulting by the fall in the
electron potential energy, is gradually released. In the process,
several redox centers, in great part organized in four protein
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Figure 1: Cellular sources of ROS production. Subcellular organelles and structural and soluble cell components all contribute to production
of a wide variety of reactive species (modified from Venditti et al. [116], with permission).

complexes inserted in the inner mitochondrial membrane,
are involved [28]. Complexes I and II transfer electrons to the
lipid-soluble carrier ubiquinone. From this, the electrons pass
through Complex III, cytochrome c (another mobile carrier),
and Complex IV, to the oxygen. The fall in electron potential
energy is used to pump protons from the mitochondrial
matrix to the intermembrane space, thus setting up a protonmotive force [29]. The process by which such a force drives
protons back into the matrix through the mitochondrial
ATP synthase leading to ATP synthesis is named oxidative
phosphorylation [30].
2.2.1. Respiratory Chain. It has now been about 50 years since
mitochondrial H2 O2 production in the presence of respiratory substrates was first recorded [31], followed shortly after
by the detection of mitochondrial generation of superoxide
radical anion [32]. The discovery that electron-transfer along
the inner mitochondrial membrane carriers is associated with
formation of ROS suggested the mitochondrial involvement
in degenerative processes linked to several diseases and aging.
The primary ROS generated within mitochondria by
univalent autooxidation of electron carriers is O2 ∙− [33],
which is converted by mitochondrial SOD into H2 O2 , which
can be turned into ∙ OH radical via the Fenton reaction:
H2 O2 + Fe2+ → ∙ OH + OH− + Fe3+

(1)

The main sites involved in mitochondrial ROS production are localized at Complexes I and III [34]. However,
succinate dependent ROS production by Complex II from
rat skeletal muscle [34] and glycerol 3-phosphate dependent
production by Complex II from several rat tissues [35] have
also been reported.
To date, the relative importance of each mitochondrial
site to ROS production is still controversial, partly due to

utilization of different assays, substrates [36], and sources
of mitochondria [37]. On the other hand, the localization
of the generators is important for establishing ROS effects
since it determines if O2 ∙− is produced in the mitochondrial
matrix or in the intermembrane space. Thus, both generators
of Complex I and Complex III release O2 ∙− into the matrix
where it can damage mitochondrial DNA, whereas Complex
III generator also releases O2 ∙− into the intermembrane space,
where it has easier access to the cytosol [36]. In their classic
work, Boveris et al. [38] reported that H2 O2 production by
isolated liver mitochondria was about 1-2% of the total oxygen
consumption during State 4 respiration and decreased during
State 3 respiration. However, lower values, around 0.1–0.2% of
the total oxygen consumption, have subsequently been found
[39].
2.2.2. Other Mitochondrial Sites of ROS Production. Experiments with isolated enzymes or mitochondria have shown
ROS production by several oxidoreductases located in mitochondrial membranes [40], whose contribution to mitochondrial ROS production is, however, unknown. They include
monoamine oxidases, which produce H2 O2 at rates that,
in brain mitochondria, may be higher than those of other
mitochondrial sources [41]; dihydroorotate dehydrogenase,
which in vitro, in the absence of coenzyme Q, its natural electron acceptor, can produce H2 O2 [42]; 𝛼-glycerophosphate
dehydrogenase, which has been reported to produce H2 O2
in mouse [37] and rat [34] mitochondria oxidizing glycerol3-phosphate; succinate dehydrogenase, which produces ROS
when isolated and incorporated in liposomes in the absence
of coenzyme Q [43]; and 𝛼-ketoglutarate dehydrogenase
complex, which has been found to generate both O2 ∙− and
H2 O2 in isolated mouse brain mitochondria [44].
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2.3. ROS Production by Peroxisomes. Although peroxisomes
have long been known as organelles involved in cellular
metabolism of H2 O2 [45], it is now clear that they are involved
in several metabolic pathways [46]. Important functions performed by peroxisomes include fatty acid 𝛽- and 𝛼-oxidation,
amino acid and glyoxylate metabolism, and synthesis of
lipidic compounds [47], and most enzymes catalyzing these
processes produce ROS during their activity [48].
Early studies indicated that about 35% of the peroxide
formed in rat liver is derived from peroxisomal oxidases [38].
Moreover, the observation that about 20–60% of the H2 O2
generated inside peroxisomes diffused to the surrounding
medium demonstrated that H2 O2 can readily cross the
peroxisomal membrane. The peroxide diffuses through the
Pxmp2 channel permeable to small solutes [49], even though
H2 O2 generated by urate oxidase localized in the peroxisome
core can be directly released in the cytosol through crystalloid
core tubules [50]. In any case, it is apparent that, despite high
content of catalase (CAT), peroxisomes are unable to prevent
the H2 O2 release.
Peroxisomes also contain xanthine oxidase [51] and the
inducible form of nitric oxide synthase (see below) [52],
which produce O2 ∙− and NO∙ , respectively. Because such
species react rapidly forming ONOO and H2 O2 gives rise
to ∙ OH radicals via Fenton reaction, peroxisomes are a
potential source of such highly reactive species. Because, if
uncontrolled, ROS and RNS are very damaging, peroxisomes,
in addition to catalase, contain other antioxidant enzymes
[50]. However, in the light of their capacity to produce
membrane permeant reactive species, such as H2 O2 and
NO∙ , it is highly likely that, under some physiological or
pathological conditions, peroxisomes may act as a source of
H2 O2 and NO∙ in living cells [50].
2.4. ROS Production by Endoplasmic Reticulum. The endoplasmic reticulum (ER) is involved in multiple functions,
such as synthesis, folding, and transport of Golgi, lysosomal,
secretory, and cell-surface proteins [53], calcium storage [54],
lipid metabolism, and, in some cell types, drug detoxification
[55].
Smooth endoplasmic reticulum presents a chain of electron transport, constituted by two systems devoted to xenobiotic metabolism and introduction of double bonds in fatty
acids, which are also able to produce ROS. Another microsomal system, which shares this ability, provides oxidative
protein folding.
2.4.1. Xenobiotic Metabolism. The metabolism of xenobiotics
generally occurs in two phases. Phase I reactions introduce
a polar group in a lipophilic substrate (AH) using O2 and a
reducing agent (RH2 ):
AH + O2 + RH2 → AOH + R + H2 O

(2)

In the reaction, known as a monooxygenase reaction, it is
involved in a system constituted by a flavoprotein (NADPHcytochrome P450 reductase) and cytochromes known collectively as cytochromes P450 (CYPs).

The Phase II reactions are conjugation reactions in which
an endogenous molecule is added to the Phase I reaction
product or sometimes directly to the xenobiotic.
In whole, the process detoxifies xenobiotics converting
them into species that are more water soluble and easier to
excrete in urine or can be conjugated with substances which
make their urinary or biliary excretion further easier.
The membranes of the endoplasmic reticulum system
were recognized as a source of H2 O2 in 1957 by Gillette et al.
[56] that assumed that the NADPH-cytochrome c reductase
might be the microsomal H2 O2 generator. However, it was
subsequently reported that O2 ∙− [57] and H2 O2 [58] could be
formed by decay of two intermediates of the catalytic cycle.
The microsomal cytochrome P450-dependent monooxygenase system is one of the major producers of ROS in the
liver cell [59]. Indeed, estimates performed using NADPH
as substrate indicated that microsomes contribute to H2 O2
production in rat liver by 45% [38].
2.4.2. Unsaturated Fatty Acid Production. In most organisms,
unsaturated fatty acids are produced by desaturases, which
convert a single bond between two carbon atoms in a fatty
acyl chain into a double bond [60]. In the ER system,
which allows for fatty acid desaturation, cytochrome b5
acts as an electron-transfer component, with two possible
modes of action. First, desaturation can be carried out by
a multienzyme system, composed of desaturase, NADH
cytochrome b5 reductase, and cytochrome b5. In the reaction,
cytochrome b5 transfers electrons by lateral diffusion, from
NADH cytochrome b5 reductase to the desaturase which
introduces carbon-carbon double bonds into fatty acids using
one molecule of O2 and forming two molecules of H2 O [61].
Secondly, many desaturases are modular proteins that are
composed of desaturase and cytochrome b5 modules [62].
The fusion of the desaturase and cytochrome b5 domains
makes the NADH cytochrome b5 reductase able to directly
transfer electrons to the catalytic site of the cytochrome
b5 fusion desaturases via the cytochrome b5-like domain
without the requirement of an independent cytochrome
b5 [63]. This can increase the rate of electron-transfer by
presenting a correctly oriented heme group with respect to
the dioxo-iron cluster, eliminating the need for diffusion and
reorientation of the reduced cytochrome b5 [63].
The two electron transport systems do not act independently of each other and cytochrome b5 may play a role
in the NADPH-dependent oxidation of xenobiotics. Indeed,
cytochrome b5 exhibits a positive action on cytochrome P450
monooxygenase reaction, which is due to the transfer of the
second of the two electrons necessary for molecular oxygen
activation to cytochrome P450 [64]. This transfer makes the
catalysis faster and reduces the time for formation of side
products, such as H2 O2 and O2 ∙− [64]. Recently, it has also
been demonstrated that NADH cytochrome b5 reductase
can leak electrons to O2 to make O2 ∙− and this can be an
additional source of O2 ∙− in vivo [65].
2.4.3. Protein Folding. Most proteins synthesized in ER are
stabilized by formation of intramolecular disulfide bonds,
process that requires oxidation of free sulphydryl groups.
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The feasibility of protein oxidative folding in intraluminal ER
milieu is ensured by an oxidized (GSSG) to reduced (GSH)
glutathione ratio higher than that within the cytosol [66]. The
formation of disulfide bonds in proteins is driven by protein
disulfide isomerase (PDI), a member of the thioredoxin
family, and endoplasmic reticulum-resident protein (Ero1p),
which is tightly associated with FAD moiety [66]. Ero1p
functions as an oxidase for PDI: oxidizing equivalents flow
from Ero1p to substrate proteins via PDI, through direct
dithiol-disulfide exchange between PDI and Ero1p [67].
The process of oxidative protein folding uses molecular
oxygen as the source of oxidizing equivalents. Indeed, Ero1p
transfers electrons from PDI to molecular oxygen by a
FAD-dependent reaction, resulting in ER protein foldinginduced oxidative stress [68]. By theoretical calculation, it
was estimated that protein thiol oxidation via PDI and Ero1
could account for up to 25% of cellular ROS produced during
protein synthesis [69].
2.5. ROS Production by Plasma Membrane. The plasma membrane is involved in several cellular processes such as cell
adhesion, ion conductivity, and cell signaling. It is also a
key site of free radical reactions because it is generally
exposed to an oxidizing environment. ROS, which in tissues
could be generated from dysfunctional cells [70], cause
oxidative damage of membrane components unless efficient
antioxidant systems are operative. The increase in membrane
permeability, caused by oxidation of lipids or structurally
important proteins, can result in a decrease in transmembrane ion gradients, loss of secretory functions, and inhibition of cellular metabolic processes.
Free radicals can be produced during the conversion
of arachidonic acid into products, such as prostaglandins,
thromboxanes, and leukotrienes, by membrane associated
enzymes such as lipoxygenase and cyclooxygenase [71]. Such
enzymes metabolize arachidonic acid released from membrane phospholipids via phospholipase A2 activity and generate ROS as by-products during arachidonic acid oxidation.
However, the main source of ROS is represented by
O2 ∙− production by the membrane-bound enzyme NADPH
oxidases. O2 ∙− production by the phagocyte enzyme is a wellknown phenomenon, which helps to kill bacterial intruders
[72].
The phagocyte NADPH oxidase is composed of two
membrane proteins gp91phox (cytochrome b558 heavy chain,
later designated as NOX2, which is the catalytic subunit of
the enzyme) and p22phox, three cytosolic proteins p67phox,
p47phox, and p40phox, and a small GTP binding protein
Rac [73]. In resting cells, the enzyme is dormant, and its
components are distributed between the cytosol and plasma
membrane. Bacterial infection induces translocation of the
cytosolic components to the phagosome membrane where
they associate with cytochrome b558 and give rise to the
catalytically active NADPH oxidase [73].
The presence of NOX2 homologs was firstly suggested
by the observation that O2 ∙− is produced in a NADPHdependent manner in nonphagocytic cells, in which NOX2
is not expressed [74]. To date, five NOX isoforms (NOX1,
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NOX2, NOX3, NOX4, and NOX5) and two related enzymes,
DUOX1 and DUOX2, have been reported and most, if not all,
isoforms were targeted to cellular membranes.
The NOX proteins constitute the only enzyme family with
the sole function of producing ROS. These proteins have
different regulation and specific subcellular localization and
generate distinct ROS [75]. NOX1, present in smooth muscle
cells and other vascular cells, NOX2, present in endothelial
and phagocytic cells, and NOX3, found in the brain and inner
ear, generate O2 ∙− . NOX4, constitutively expressed and active
in vascular smooth muscle and endothelial cells, is responsible for the basal production of H2 O2 . NOX5, identified
in human immature lymphatic tissues and endothelial cells,
produces H2 O2 in a Ca2+ dependent fashion. The DUOX1 and
DUOX2, originally isolated from the thyroid, produce H2 O2
that oxidizes iodide during thyroid hormone synthesis.
The phagocyte NADPH oxidase, when activated, generates quantities of O2 ∙− and H2 O2 accounting for a significant
fraction (10–90%) of total oxygen consumption of neutrophils, macrophages, and microglia, but the contribution
of such and other NADPH oxidases to total cellular ROS
production in resting or during activation is less clear [23].
It has also been reported that arachidonic acid [76] and
its metabolites generated by lipoxygenase [77] and cyclooxygenase [78] stimulate the generation of ROS by NOXs, thus
revealing the existence of an interconnecting signaling system
between eicosanoids and NOXs.
2.6. ROS Production by Lysosomes. Although lysosomes are
involved in several functions, until recently they were considered as pure sites for terminal degradation of macromolecules
[79].
On rat liver membranes, flavins, ubiquinone, and a b-type
cytochrome [80] form a functional electron transport system,
starting with the donor NADH and ending to acceptor
O2 through the sequence FAD→cytochrome b→ubiquinone
[81]. The role of this redox chain is to support proton accumulation within lysosomes [81] to maintain an optimal pH
for the acidic hydrolases [79]. The electron transport chain
appeared to give rise to ∙ OH radical, which required the transfer of three electrons to molecular oxygen, whereas O2 ∙− was
not detected. This does not exclude the intermediate existence
of O2 ∙− , because the acid pH-milieu inside lysosomes favors
spontaneous dismutation of O2 ∙− to H2 O2 , which is cleaved
by intralysosomal ferrous iron into ∙ OH [82].
2.7. RNS Production. NO∙ is produced from the metabolism
of the amino acid, L-arginine. The enzymes catalyzing this
process, known as nitric oxide synthases (NOS), convert Larginine into L-citrulline and NO∙ by a 5-electron oxidation
of a guanidine nitrogen of L-arginine [83].
To date, three isoforms of nitric oxide synthase have been
identified. Two isoforms, neuronal NOS (nNOS; type I NOS)
and endothelial NOS (eNOS; type III NOS), are expressed
constitutively and regulated by the interaction of Ca2+ with
calmodulin [84]. The other isoform, inducible-NOS (iNOS;
type II NOS), is induced in response to infection, inflammation, or trauma and is not regulated by Ca2+ because it forms a
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complex with calmodulin at very low concentrations of Ca2+
[84].
NO∙ generated by the NOS isoforms located in different
cell types plays different roles. NO∙ generated by nNOS
in neurons serves in communication between nerve cells,
whereas the free radical generated by iNOS in macrophages
and smooth muscle cells contributes to their killing mechanism, and NO∙ generated by eNOS in endothelium, brain,
and heart relaxes blood vessels and maintains normal blood
pressure [84].
The subcellular distribution of NOS is dynamically regulated so that the enzymes are exposed to different concentrations of ROS depending on where in the cell they are
localized. For example, eNOS is mainly found in plasma
membranes of cardiac and endothelial cells and, in both cells,
it is localized at the caveolae of the sarcolemma and T tubules,
where it is associated with caveolin, the structural protein of
caveolae [85]. However, as a result of different stimuli, eNOS
shuttles between caveolae and distinct intracellular sites and
it is likely that the selective movement of eNOS serves to
determine specific responses to the agonists [86].
Interestingly, the study of the subcellular localization of
iNOS showed that during sepsis a substantial amount of the
enzyme of the rat hepatocytes localizes to peroxisomes [52],
but subsequently it was found that only monomeric iNOS
is associated with peroxisomes. Peroxisomal iNOS could be
reactivated in vitro, but it had a lower specific activity than
iNOS in the soluble pool [87]. Thus, uncoupled or deficient
iNOS may be targeted to the peroxisome, even though it
is possible that iNOS plays a role in the regulation of peroxisomal function. Furthermore, there is growing evidence
supporting the existence of mitochondrial NOS (mtNOS)
and its involvement in the regulation of mitochondrial as well
as cellular functions in several tissues [88].
Some functions of NO∙ in signaling and regulation of
cell function are performed through cGMP-independent
pathways including those involving mitochondria [89]. At
physiological concentrations, most mitochondrial effects of
NO∙ are exerted on the respiratory chain. First, NO∙ competes with O2 for the binding site at the binuclear center
of cytochrome 𝑐 oxidoreductase, leading to a reversible
inhibition of cytochrome 𝑐 oxidase activity [90]. Secondly,
NO∙ , reacting with respiratory Complex III, inhibits electrontransfer and enhances O2 ∙− production [91]. NO∙ also gives
rise to protein nitrosation, reacting reversibly with the nucleophilic centers in protein thiol residues [92], and mitochondria, treated with NO∙ donors, exhibit S-nitrosation and
inhibition of Complex I [93]. Moreover, the reaction of NO∙
with O2 ∙− , which is formed by the mitochondrial respiratory
chain, leads to the switch from reversible inhibition of
cellular respiration by NO∙ to the pathological inhibition of
mitochondrial function by ONOO− [94].

3. Role of ROS Sources in Oxidative Stress and
Tissue Dysfunction
Tissue oxidative damage and consequent dysfunction shown
in various pathological conditions depend on increased

Oxidative Medicine and Cellular Longevity
cellular production of ROS and RNS or on impaired removal
of such species. Extensive information is available on mitochondrial ROS production and its relationship with mitochondrial oxidative damage and dysfunction. Because mitochondria are required for oxidative energy production and
multiple biosynthetic reaction pathways in aerobic cells, it is
understandable that a disturbance of mitochondrial function
can lead to impaired cell function and development of several
pathologies [22].
However, the larger available information and relevance
of mitochondrial function for cell viability do not make mitochondria the main source responsible for tissue dysfunction
in conditions of oxidative stress. Indeed, even increases in
reactive species production by other cellular sources can
cause cellular alterations. On the other hand, available data
about ROS and RNS production have mostly been obtained
using isolated organelles or cellular cultures and, until
recently, the direct measurement of ROS in living systems
remained difficult due to the lack of adequate methodology.
The recently introduced fluorescent protein-based probes for
H2 O2 and GSH/GSSG redox state [95] will likely facilitate
reliable organelle-specific ROS measurements, but presently
we are not able to provide a well-founded answer to the
question concerning the role played by the various sources
of reactive species in tissue dysfunction.
3.1. Mitochondria. Normally, the rate of mitochondrial ROS
generation is rather low and results in minimal damage,
because mitochondria have a highly efficient antioxidant
defense system able to scavenge a large number of the
ROS produced. However, in several circumstances, high
rates of ROS production occur, so that a substantial part of
oxidants may escape the scavenging systems and compromise
important mitochondrial functions. Moreover, even though
it is extremely unlikely that ∙ OH radicals can be released by
mitochondria, oxidative damage to components of cytoplasm
and other cellular structures can result from mitochondrial
leakage of other ROS, such as H2 O2 that is able to readily cross
mitochondrial membranes and reach such structures where,
in the presence of Fe2+ ligands, it can generate ∙ OH radical.
Information on the role of an increased ROS production
in decline of mitochondrial function and cellular derangement is supplied by experimental work dealing with myocardial ischemia-reperfusion (IR) injury.
Myocardial ischemia occurs when myocardial oxygen
demand exceeds oxygen supply. Unless reversed, this situation results in irreversible tissue injury and myocardial
infarction. Although restoration of blood flow is necessary
to salvage ischemic tissues, it may create another form of
myocardial damage, termed “reperfusion injury” [96], which
is partly due to the generation of toxic oxygen radicals [97].
Initially, O2 ∙− was postulated to be the species responsible
[98], but now it is clear that the several ROS and RNS are
involved in reperfusion injury [99]. ROS are produced in
reperfused myocytes from several sources, including xanthine oxidase, NADPH oxidase, and mitochondria. ROS may
be produced by xanthine oxidase which is activated during
hypoxia [98]. NADPH oxidases account for an important
part of the ROS formed during ischemia-reperfusion [100].
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However, there is now strong evidence that mitochondrial
ROS generation plays a critical role in damaging cellular
components and initiating cell death.
The proposal that the respiratory chain is a major source
of ROS during reperfusion of ischemic myocardium [97]
was supported by the observation that a generation of
oxygen radicals was induced in vitro upon reoxygenation of
mitochondria isolated from hearts that had been subjected to
ischemia [101]. Further support was obtained demonstrating
by electron paramagnetic resonance that resumption of
mitochondrial oxidative phosphorylation upon postischemic
reflow can be a source of oxygen radicals in intact rabbit
hearts [102].
Because mitochondrial ROS generation depends on the
degree of reduction of the autoxidizable electron carriers,
the increased reduction of the respiratory chain associated
with ischemia promotes ROS generation upon the respiration
resumption. It was proposed that ROS generation is induced
by interaction with ubisemiquinone, which accumulates in
mitochondria during ischemia because of respiratory chain
inhibition [103]. This ROS generation ends rapidly when
the mitochondrial components of the respiratory chain are
reoxidized. However, it is long-lasting mitochondria that have
accumulated large amounts of reducing equivalents, so that
the severity of reperfusion-induced oxidative damage and
mitochondrial dysfunction should increase with ischemia
duration. In fact, it was determined that mitochondrial
function impairment was enhanced when coronary occlusion
periods increased [104] and mitochondria lipid peroxidation
increased gradually with ischemia duration [105]. These
changes were well related to a gradual decline in mitochondrial respiration, which reflected damage to electron
transport chain components. It was also shown that, after
reperfusion of ischemic heart, functional recovery of the
tissue was inversely correlated to mitochondrial derangement [105], supporting the idea that heart performance is
strongly conditioned by mitochondrial functionality. Further
support was provided by the observation that the antioxidant protection of mitochondrial function was associated
with decreased impairment of cardiac function following
ischemia-reperfusion [106]. Thus, mitochondria are a site
of reperfusion-induced oxidative damage, whose severity
increases with ischemia duration.
It is likely that mitochondrial oxidative damage and dysfunction is due to ∙ OH radicals produced within mitochondria. These oxyradicals are highly reactive, short-lived species
and are expected to cause damage at or near the site of
formation. Therefore, they may inactivate components of the
respiratory chain, enzymes of the Krebs cycle, and other mitochondrial proteins, leading to mitochondrial dysfunction.
NOS stimulation [107] and inhibition of mitochondrial
function by both NO∙ [108] and ONOO− [109] upon ischemia-reperfusion were reported, suggesting that the reduction
in mitochondrial respiration induced by ischemia-reperfusion also depends on increased RNS production.
RNS involvement in reperfusion-linked alteration in
mitochondrial and tissue function was demonstrated studying ischemia-reperfusion in the presence of the NOS inhibitor, N𝜔 -nitro-L-arginine (L-NNA) [110]. Indeed, L-NNA
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improved heart functional recovery and mitochondrial respiration protecting mitochondria from the oxidative and
nitrosative damage.
3.2. Strengthening of Mitochondrial Oxidative Damage. In
light of the aforementioned results, the mechanism which,
during reperfusion, causes tissue damage and dysfunction
appears to be a positive feedback loop. Indeed, the concomitance of reflow-mediated perturbations, such as NOS
activation and increased ROS production, strengthens mitochondrial damage and dysfunction thus leading to increased
tissue derangement. Furthermore, there is evidence that
other mechanisms, involving mitochondria, are able to alter
the tissue susceptibility to stressful conditions, leading to
pathological consequences.
A mechanism of ROS production strengthening is the
process named ROS-induced ROS release (RIRR) [111].
RIRR is generated by circuits requiring mitochondrial membrane channels, including nonspecific mitochondrial channels called the mitochondrial permeability transition (MPT)
pores [112] and the inner membrane anion channel (IMAC)
[113].
A condition that leads to RIRR is the exposure to high
oxidative stress resulting by an increase in ROS that reaches a
threshold level that triggers the opening of MPT pore. Under
oxidative stress, mitochondrial Ca2+ overload takes place,
which depresses mitochondrial function [114] and triggers
several processes, including MPT pore opening [111]. This, in
turn, causes collapse of mitochondrial membrane potential
and transient increase in ROS generation [111]. In addition to
ROS effects in mitochondria where the RIRR is originated,
the ROS release into cytosol, which seems to occur through
IMAC [115], can lead to RIRR activation in the neighboring
mitochondria. ROS trafficking between mitochondria could
constitute a positive feedback mechanism for enhanced ROS
production potentially leading to significant mitochondrial
and cellular injury.
Although externally generated O2 ∙− and H2 O2 can readily
cross mitochondrial membranes, it is likely that H2 O2 is the
messenger molecule leading to whole cell RIRR because of
its longer lifetime in the cytosol and higher permeability
in membrane lipids [116]. In addition, it is conceivable that
a phenomenon similar to RIRR can also depend on NO∙ .
Indeed, NO∙ diffuses from mitochondria to cytosol, as well as
from cytosol to mitochondria, a process called mitochondriacytosol NO∙ cross talk [117]. Within mitochondria, NO∙ is
able to act as an inducer of permeability transition [118],
through a direct effect on the MPT pore and an indirect effect
secondary to oxidative phosphorylation inhibition [119].
Excess oxidants may also augment mitochondrial ROS by
upregulating the expression of the lifespan regulator, the 66kDa isoform of growth factor adaptor Shc (p66Shc ) protein,
which has been implicated in the development of aging and
aging-related diseases [120]. The protein resides mainly in
the cytosol [121], with a small fraction localized in the mitochondrial intermembrane space [122]. The protein is kept by
thioredoxin (TRX) 1 and glutathione in the inactive reduced
state. However, stress factors, including ROS, can increase the
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expression of the protein that is activated by thiol oxidation
which causes a dimer-tetramer transition [123]. Activated
p66Shc translocates to the mitochondrial intermembrane
space where it associates with cytochrome c producing H2 O2 ,
which can trigger MPT pore opening [121]. The importance
of p66Shc in vivo has been demonstrated by observation
that knockout of p66Shc increases lifespan, reduces H2 O2
generation, and enhances survival to oxidant stress [120].
Mitochondrial ROS production can be increased by
mitochondrial fission. As it is known, mitochondrial shape
can be modified by fusion and fission, resulting in elongated,
interconnected mitochondrial networks and fragmented, discontinuous mitochondria, respectively [124].
Specific changes in mitochondrial shape suggest that
morphology and function of mitochondria are closely linked,
so that loss of fusion or division activity results in dysfunctional mitochondria [125]. An explanation for the importance
of mitochondrial fusion could be the need for exchange of
intermembrane space and matrix contents between mitochondria, so that defects and transient stresses may be
partially buffered. On the other hand, mitochondrial division
should create organelles of the appropriate size for transport
along actin or microtubule networks [125].
The fission process seems to have a remarkable impact
on ROS metabolism. Indeed, it seems that oxidative stress
causes mitochondrial fragmentation via differential modulation of mitochondrial fission-fusion proteins [126], leading to
reduced respiratory capacity and enhanced ROS production
[127]. It has also been suggested that changes in mitochondrial network structure provide an example of ROS-mediated
ROS generation where ROS play a role in mitochondrial
fission to augment ROS generation from restructured mitochondria [128].
NO∙ appears to play opposite roles in mitochondrial
fission-fusion. Indeed, it may enhance mitochondrial fragmentation and cell death in neurodegenerative diseases by its
effects on dynamin-related protein-1 (Drp1), which promotes
mitochondrial fission [129]. In myogenesis, NO∙ has the
opposite effect promoting the fusion of mitochondria into an
elongated network by inhibiting Drp1-mediated fission [130].
3.3. Other Cellular ROS Sources. Until recently, the functional
significance of ROS sources different from mitochondria has
received lesser attention. However, in recent years, greater
attention has been turned to the potential role of ROS
produced by outer sources in cell signaling and dysfunction.
Moreover, there are reasons to think that ROS, released
by mitochondria, interact not only with other mitochondria
but also with other sources of ROS. It is now apparent that
there is a substantial interplay between ROS sources, so that
activation of one can lead to activation of the others, resulting
in RIRR that further increases ROS production and oxidative
stress (Figure 2).
3.3.1. Peroxisomes. Normally, peroxisomes display mechanisms to maintain the equilibrium between production and
scavenging of ROS, but in some situations antioxidant system
capacity is overwhelmed. One such situation is the increase in
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peroxisome numbers stimulated by a heterogeneous class of
chemicals, known as peroxisome proliferators, whose effects
are mediated by peroxisome proliferator activated receptors
(PPARs) which belong to the family of nuclear transcription
factors [131]. Whereas the expression of the genes of the lipid
𝛽-oxidation, particularly of acyl-CoA oxidase, is induced 10–
30-fold depending on compound and dosage, the catalase
does not exceed 1-2-fold induction [132]. The disproportionate increase of H2 O2 -generating oxidases in comparison to
H2 O2 -scavenging catalase was suggested to be responsible for
oxidative stress leading to the development of hepatic tumors
in rodents treated with peroxisome proliferating compounds
[133].
The central event in the carcinogenesis seems to be the
activation of PPAR𝛼, because PPAR𝛼−/− mice, fed a diet
containing a potent nongenotoxic carcinogen, are refractory
to both peroxisome proliferating effect and carcinogenesis
[134]. This is consistent with resistance to the carcinogenic
effect of peroxisome proliferators of primates and humans,
which have low hepatic levels of PPAR𝛼 [135].
Peroxisomes rely heavily on cross talk with other subcellular organelles, notably mitochondria, to further metabolize
the end products of their metabolism [136]. Peroxisomes
and mitochondria also share an intricate redox sensitive
relationship [137] and seem to cooperate in the maintenance
of cellular ROS homeostasis. It has been suggested that when
mitochondrial H2 O2 generation increases and the system
constituted by glutathione peroxidase (GPX) and glutathione
reductase (GR), limited by GSH and NADPH levels, is unable
to cope with the increased H2 O2 , the peroxide that escapes
across the mitochondrial membrane may be degraded by
catalase in the peroxisomes [138].
Actually, the very high content of catalase inside peroxisomes suggests that these organelles may serve as an intracellular sink for H2 O2 . This idea is supported by the finding that
overexpression of catalase in pancreatic islets of transgenic
mice produces a marked protection of islet insulin secretion
against H2 O2 [139]. However, other studies indicate that
peroxisomes represent a potential source of oxidative stress,
causing cell damage or modulating redox sensitive pathways
[140], and disturbances in peroxisomal redox metabolism
lead to mitochondrial oxidative stress [141]. For example,
human fibroblasts treated with a catalase inhibitor not only
exhibit high levels of cellular H2 O2 , protein carbonyls, and
peroxisomal numbers but also increase mitochondrial ROS
levels and decrease mitochondrial aconitase activity and
inner membrane potential, demonstrating that peroxisome
oxidative imbalance elicits oxidative damage throughout the
cell and in particular to mitochondria [142]. Peroxisome dysfunction also has a profound impact on mitochondrial function, as demonstrated by the observation that Pex5p (peroxisomal cycling receptor) knockout mice possess increased levels of mitochondria, which show structural abnormalities and
alterations in the expression and activity of respiratory chain
complexes [143]. Mitochondrial oxidative phosphorylation
is also impaired, with consequent increase in mitochondrial
ROS generation, in X-linked adrenoleukodystrophy, the most
common peroxisomal disorder [144].
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Figure 2: ROS propagation among mitochondria and other ROS sources. Mitochondrial ROS production can cause collapse of mitochondrial
membrane potential and increase in ROS generation. ROS produced in only small number of mitochondria can influence neighboring
mitochondria and other cellular organelles, eventually propagating the ROS surge to the whole cell (modified from Venditti et al. [116],
with permission).

3.3.2. Endoplasmic Reticulum. ROS production in endoplasmic reticulum is normally neutralized by antioxidant system
components, but in some conditions there is an excessive
production of ROS leading to oxidative stress. An example
is provided by the accumulation of unfolded and misfolded
proteins in the ER lumen, a condition called ER stress,
which has been associated with several diseases, such as
neurodegenerative disorders, stroke, bipolar disorder, cardiac
disease, cancer, diabetes, and muscle degeneration [145].
It is well documented that only properly folded proteins
can be exported to the Golgi apparatus for further modification and translocated to their destined sites, while misfolded
or incompletely folded proteins are retained in the ER [146].

ER stress can be due to extracellular stimuli and changes in
intracellular homeostasis, including ER Ca2+ , glycosylation,
energy stores, redox state, and expression of proteins that are
prone to misfolding. In response to ER stress, cells activate an
adaptive response, the unfolded protein response (UPR), to
resolve the protein folding defect. The UPR attenuates protein
synthesis to reduce protein load, induces ER chaperone genes
to accelerate protein folding, and degrades misfolded proteins
by the ER-associated degradation (ERAD) machinery [24].
However, when ER stress is too severe or prolonged, processes
need to be elicited to remove overstressed cells [147].
The ER protein folding homeostasis and ER redox state
are closely linked since disulfide bond formation in the ER
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lumen is highly sensitive to altered redox balance so that both
reducing and oxidizing reagents disrupt protein folding and
cause ER stress [148]. During oxidative protein folding, the
thiol groups on cysteines of substrate peptides are oxidized
and H2 O2 is generated as a by-product. During ER stress,
dysregulated disulfide bond formation and breakage may lead
to oxidative stress by generating large amounts of H2 O2 and
depleting ER GSH [149].
Studies have indicated that ROS, produced in the ER
during ER stress, subsequently caused mitochondrial dysfunction, impairing the respiratory chain, and increase mitochondrial ROS production particularly when ER stress is
severe or sustained. Indeed, the increase in ROS levels causes
a Ca2+ influx from the ER into the cytoplasm through the
ER-localized channels and a large portion of the ion is taken
up by the mitochondria resulting in ROS production [145].
Mitochondrial ROS can in turn increase further the ER stress
response thereby amplifying ROS accumulation [150]. Thus,
it seems that the ER is placed in a vicious cycle where ER stress
can be caused by oxidative stress and increases the perturbed
redox state. This process is likely favored by the existence
of close ER-mitochondria contacts [151], which facilitate the
ROS shift between organelle compartments.
ROS production can also be amplified when exposure
to a variety of foreign compounds, such as phenobarbital
(PB), increases the P450 levels. Induction by PB causes
proliferation of the smooth endoplasmic reticulum with
incorporation of the structural gene products (the P450s) into
microsomal membrane [152]. In rat liver, increases in P450
levels, microsomal and mitochondrial protein content, and
alteration of mitochondrial composition were reported [153].
PB-induced increase in P450 levels enhances H2 O2 production by NADPH-supplemented liver microsomes [154] and
gives rise to an increase in peroxidative reactions, involving
the whole cell [153].
Although these results suggest a damaging role of P450
induction in hepatic tissue, a consequence of the high rates
of production of ROS by P450 is its own labilization and
subsequent rapid inactivation. Indeed, ROS, generated by
some cytochrome P450 forms, are able to lead to oxidative
inactivation of the P450 themselves modifying apoenzymes
or oxidizing the heme groups. Attack on sulfur-containing
amino acids results in the conversion of P450 into P420 [155],
whereas attack on the heme moiety leads to its breakdown
and loss of microsomal P450 [156]. Such a loss was observed
during microsome catalytic turnover under the action of
oxygen species generated at the hemoprotein active center
[157]. The cytochrome P450 self-inactivation is important
in situations in which increases in P450 levels occur due to
uptake by the organism of enhanced amounts of xenobiotics.
Although P450 induction serves to help “detoxication”
of xenobiotics, it can be considered an adaptive response
that has survival value for the organism, as it can also
increase “toxification” [158]. First, cytochrome P450 generates toxic chemically reactive intermediates from relatively
unreactive compounds. Moreover, because cytochrome P450
inducibility is generally higher than the conjugating enzyme
inducibility [159], there is a potential imbalance between
the rate of generation of chemically reactive intermediates
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and their rate of inactivation and removal. The reactive
metabolites that are not conjugated and the ROS released by
P450 may attack proteins, membrane components, or nucleic
acids, leading to cytotoxicity, mutations, and cancer [160].
Therefore, P450 inactivation may be considered a mechanism
to prevent cellular accumulation of high levels of the enzyme.
Moreover, it appears to be part of a concerted adaptive
response to oxidative stress, consisting of repression of ROSgenerating systems and induction of antioxidant defenses, as
observed in human hepatoma HepG2 cell lines, expressing
CYP2E, the ethanol-inducible cytochrome P450 [161].
3.3.3. Lysosomes. Lysosomes contain the major pool of low
mass redox-active intracellular iron, arising from the intralysosomal degradation of iron-containing proteins, such as
ferritin, and iron-rich organelles, such as mitochondria
[162]. Iron accumulation predisposes lysosomes to oxidantinduced damage and rupture with consequent cellular injury.
Indeed, some H2 O2 , formed outside the organelles and escaping the extralysosomal degradation, can diffuse into lysosomes and, together with that formed directly in the lysosomes, can generate ∙ OH radicals by Fenton reaction. The
ensuing oxidative damage on the lysosomal membranes leads
to membrane permeabilization with release to cytosol of
hydrolytic enzymes and low mass iron. This can relocate to
other cellular sites, causing site-specific ∙ OH production and
oxidative damage in conditions of H2 O2 production.
It seems that H2 O2 formation and lysosomal destabilization are important for the radiation-induced cellular injury
and death [163], which for a long time have been considered
to depend on ∙ OH formation due to radiolytic cleavage
of water. Indeed, radiation, besides ∙ OH radicals, produces
significant amounts of H2 O2 [164], which can enter the
lysosomal compartment and cause membrane permeabilization. Employing a model of irradiated murine histiocytic
lymphoma (J774) cells [163], it was found that the cells
irradiated twice demonstrated progressive lysosomal damage
from 2 h after the second irradiation, which in turn resulted
in extensive cell death [163]. Irradiation-induced lysosomal
disruption and cell death were significantly reduced by incubation with desferrioxamine conjugated with starch which
forms a stable complex with iron and renders the metal
inactive [163]. The protective effect of iron chelators against
ionizing radiation damage was subsequently confirmed on
several cell lines previously exposed to salicylaldehyde isonicotinoyl hydrazone, a lysosome targeted iron chelator [165].
3.3.4. NADH-Oxidase. Although multiple sources of ROS
during ischemia-reperfusion have been identified, convincing evidence supports NADPH oxidases as important contributors to oxidant generation in several tissues, including
cardiac tissue [166]. However, depending on the phase of IR
injury, NADPH oxidases can be either detrimental or protective, shown to have a double-edged role. Low ROS levels
are cardioprotective in pre- and postconditioning therapies,
while high ROS levels are deleterious and lead to cardiomyocyte death [167]. In addition to the ROS level, the types
of NOX expressed in cardiomyocytes and their localization
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are also important in determining the cell fate. In cardiomyocytes, three NOXs are expressed, NOX1 and NOX2, predominantly localized to the plasma membrane, and NOX4, which
is constitutively active and is localized on the intracellular
membranes of organelles [168]. Although the role of NOX
isoforms in ischemia-reperfusion has not yet clarified, a study
showed that deleterious effects of NOX1 and NOX2 occurred
during reperfusion phase in agreement with the idea that
oxygen supply during reperfusion provides substrate for
NOX-mediated ROS generation [169]. Moreover, indications
were also obtained that NOX2 generated higher levels of ROS
than NOX1, leading to direct myocardial damage [169].
Several examples of interplay between mitochondrial and
NOX-derived ROS have been reported [170]. In the whole,
they suggest the presence of a feedforward cycle in which
NADPH oxidases increase mitochondrial ROS that further
activate cytoplasmic NADPH oxidases and increase cellular
ROS production.
The NADPH oxidase involvement in the ROS-induced
ROS production is very well documented. For example,
exposure of smooth muscle cells and fibroblasts to exogenous
H2 O2 activates these cells to produce O2 ∙− via a NADPH oxidase [171]. This mechanism could help to explain why micromolar concentrations of H2 O2 cause oxidant-mediated injury
to many different types of cells during chronic oxidative
stress. Moreover, H2 O2 -induced NADPH oxidase activation
in nonphagocytic cells could be an important mechanism by
which the degree of oxidative stress, as well as the subsequent
cellular damage, is amplified during inflammatory disorders.
It was also observed that endothelial levels of xanthine
oxidase, a source of H2 O2 and O2 ∙− , depend on NADPH
oxidase [172]. The study of the mechanism showed that H2 O2
was able to induce transformation of xanthine dehydrogenase
into xanthine oxidase [173]. The observation that increase in
O2 ∙− production was a late effect of cell exposure to H2 O2
suggested that the peroxide not only stimulated conversion
of xanthine dehydrogenase into xanthine oxidase but also
activated the NADPH oxidase, leading to prolonged H2 O2
production and sustained xanthine dehydrogenase conversion [173].

4. ROS as Signaling Molecules
ROS are now appreciated as signaling molecules that regulate
a wide variety of physiological functions. Indeed, they play
crucial roles in gene activation [174], cellular growth [175],
and modulation of chemical reactions in the cell [176]. They
also participate in blood pressure control [177], are mediators
in the biosynthesis of prostaglandins [178], function in
embryonic development [179], and act as signaling molecules
within the individual cell and among cells during their
lifespan [180].
An important development in the field of ROS beneficial
effects was the discovery that, in organisms from simple
bacteria to complex mammals, ROS are able to induce redox
sensitive signal cascades leading to increased expression of
antioxidant enzymes. The increase in effectiveness of the
antioxidant defense system provided by this genetic response
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enables cells to survive an oxidant exposure that would
normally be lethal.
In mammals, gene transcription determining cell survival
can be activated by ROS in two ways: either via transcription
factors, which can interact directly with specific DNA motifs
on promoters of target genes, or via activation of mitogenactivated protein kinase cascades, which in turn activate
transcription factors that trigger target gene transcription
[181].
There are two ideas concerning the mechanism by which
ROS initiate cellular signaling, namely, modification of target
protein molecules and changes of intracellular redox state
[182], even though the distinction between them is not easy.
While ROS, such as ∙ OH, may cause irreversible damage
to macromolecules with low specificity, the main target of a
mild oxidant, such as H2 O2 , is thiol groups of protein cysteine
residues. Oxidation of these residues forms reactive sulfenic
acid (-SOH) that can form disulfide bonds with nearby
cysteines (-S-S-) or undergo further oxidation to sulfinic
(-SO2 H) or sulfonic (-SO3 H) acid. These modifications result
in changes in structure and/or function of the protein. With
the exception of sulfonic acid and to a lesser degree sulfinic
acid the modifications are reversible by reducing systems
such as thioredoxin and peroxiredoxins [183].
The cytosol redox state is normally achieved by the
“redox-buffering” capacity of intracellular thiols, such as
GSH and thioredoxin, which counteract cellular oxidative
stress by reducing H2 O2 . The high ratios of reduced to
oxidized forms are maintained by the activity of GSH reductase and TRX reductase, respectively. Accumulating evidence
suggests that GSH and TRX participate in cell signaling
processes. GSH can regulate redox signaling by alterations
both in the level of total GSH and in the ratio of its reduced to
oxidized forms, while TRX can regulate the activity of some
proteins by directly binding to them [182].
Whatever the mechanism by which ROS initiate cell
signaling, there is increasing evidence that ROS cellular levels
are strongly linked to the regulation of cellular antioxidant
levels. A well-known example of this phenomenon is Nrf2.
This transcription factor regulates the expression of several
antioxidant and detoxifying genes by binding to promoter
sequences containing a consensus antioxidant response element [184]. In turn, the subcellular localization and hence
activity of Nrf2 are at least in part regulated by its interaction
with specific reactive cysteine residues on an inhibitory
protein called Keap1 [185].
Interestingly, ROS not only are involved in the regulation
of the expression of antioxidant genes but also interact
with critical signaling molecules such as MAP kinases, PI3
kinase, PTEN, and protein tyrosine phosphatases, to initiate
signaling in several cellular processes, including proliferation
and survival [186].
4.1. ROS Role in Protection against Tissue Excessive Dysfunction. An enhanced ROS production in a cellular site can
involve further ROS production by other cellular sources
giving rise to a self-destructive phenomenon as well as the
propagation of a fire in a room containing inflammable
material. If, as in the fire example, it occurs to confine the
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more dangerous focuses and, above all, avoid that the fire
reaches the other rooms and the entire house catches fire,
the cell exposed to oxidative stress should be equipped with
mechanisms able to avoid its death or that of surrounding
cells, which should lead to excessive tissue dysfunction.
Several results indicate that ROS-linked mechanisms
are operative to provide tissue protection against excessive
dysfunction, in which mitochondrial systems seem to play a
major role.
4.1.1. Mitoptosis. High mitochondrial ROS production triggers opening of the MPT pore leading to potentially significant mitochondrial and cellular injury. However, in many
cases mitochondrial swelling due to megachannel opening
is a signal for programed mitochondrial destruction [187], a
phenomenon called mitoptosis [188], which was proposed to
represent a line of the antioxidant defense [70].
It is well-established that the mitochondrial population
is heterogeneous with regard to its characteristics because it
consists of fractions with different properties [189]. Studies
on liver mitochondrial fractions, resolved by differential
centrifugation, suggested that the light fractions, with low
respiratory activity, contained transitional forms in the process of development into the heavy mitochondrial structures
with high respiratory activity [190]. The heavy fraction
also exhibited the lowest antioxidant level [190, 191] and
the highest rates of H2 O2 production and susceptibility to
Ca2+ -induced swelling [190]. It is interesting that conditions
leading to increased ROS production, such as exercise [192]
and cold exposure [193, 194], decrease the amount of heavy
mitochondria and increase that of light mitochondria in rat
muscle and liver, respectively. This suggests that, in rat tissues,
conditions of increased ROS production favor the substitution of the oldest ROS-overproducing mitochondria with
neoformed mitochondria endowed with a smaller capacity
to produce free radicals [190]. If so, the mechanism that,
during oxidative stress, enhances the swelling of Ca2+ -loaded
mitochondria constitutes a negative feedback loop. In fact,
the perturbation itself, represented by an enhancement in
ROS generation, should lead to accelerated mitoptosis, thus
limiting tissue oxidative damage during oxidative stress.
4.1.2. Autophagy. Autophagy is a cytoprotective process by
which organelles and bits of cytoplasm are sequestered
in double-membrane vesicles, called autophagosomes, and
subsequently delivered to lysosomes for hydrolytic digestion
[195]. Autophagy serves as an adaptation strategy for stress
conditions, such as amino acid starvation, unfolded protein
response, or viral infection, and it is widely accepted that
it regulates cell homeostasis by adjusting organelle number
and clearing damaged structures. However, if autophagy
prevents or promotes cell death and if it is a selective or
nonelective process are still controversy questions. It is likely
that autophagy can be involved in both survival and death.
It assures cell survival when it removes damaged organelles
that might activate programed cell death as apoptosis (type
I cell death) [196]. On the other hand, it promotes cell death
when it is excessive and deregulated, since enzymes leaking
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from lysosomes, such as cathepsins and other hydrolases,
can initiate mitochondrial permeabilization and, eventually,
apoptosis [197].
Clearly, autophagy leading to cell death is not selective,
whereas the controversy persists about autophagy developing as a survival process. The observation that autophagosomes often contain various cytoplasmic elements, including cytosolic proteins and organelles [198], suggested that
autophagy is a nonspecific form of lysosomal degradation. However, subsequent observations showed that the
autophagy can be a selective process in which specific proteins or organelles are delivered to the autophagosome for
degradation [197].
Such selective types of autophagy include selective degradation of mitochondria (mitophagy) [197], peroxisomes
(pexophagy) [199], endoplasmic reticulum (reticulophagy)
[200], or even nucleophagy during which parts of the nucleus
are specifically degraded by an autophagic process [201].
Mitochondria subjected over time to multiple attacks
become damaged and possibly dangerous to the cell, so
that elimination of such mitochondria is essential to protect
cells from the harm due to their disordered metabolism.
The view that autophagic processes can remove damaged
and dysfunctional mitochondria was directly confirmed by
experiments in which selected mitochondria inside living
hepatocytes were subjected to laser-induced photodamage
[202]. Mitochondrial depolarization and inner membrane
permeabilization seemed to be required for autophagy signaling [202] suggesting involvement of MPT pore opening and
swelling in the mitophagy.
A growing body of evidence now suggests that processes of autophagy and/or apoptosis involving other cellular
organelles are able to protect tissues in conditions leading to
oxidative stress.
Peroxisomes were the first organelles for which selective
organelle degradation by autophagy was described [203].
Studies on selective degradation of peroxisomes in methylotrophic yeasts showed that when grown on methanol
as the carbon source, yeast species included several large
peroxisomes containing the enzymes necessary to assimilate
methanol. When methanol grown cells were shifted to a
different carbon source, such as glucose or ethanol, whose
metabolism did not involve these peroxisomal enzymes,
pexophagy occurred [199]. Hence, this autophagic process
occurred during a rapid intracellular remodeling process to
remove organelles containing enzymes no longer needed for
methanol utilization.
More recent studies indicate that autophagic degradation
of peroxisomes in yeast also occurs as part of cellular housekeeping [204]. It was observed that, during chemostat cultivation of wild type H. polymorpha cells, entire peroxisomes
were constitutively degraded by autophagy during normal
vegetative growth, likely to enable the cells to rejuvenate the
peroxisome population.
There is convincing evidence that ER stress and reticulophagy induction are strongly linked. For example, it was
reported that, during unfolded protein response to ER stress,
induced by DTT, portions of the ER were sequestered by
double-membrane vesicles, similar to autophagosomes [200].
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The presence of ribosomes on the outer membrane of these
structures suggested a role of the ER as a membrane source
for this type of autophagosomes, which subsequently fused
with the vacuole releasing its content for degradation. This
process was highly selective as cytosol and other organelles
were not included into the vesicles [200]. Not much is known
about ER degradation and its role in ER maintenance, but
it is possible that this selective pathway serves to degrade
damaged portions of the ER or resize it after the folding stress
induced enlargement.
Although numerous factors and signaling pathways contribute to autophagy induction in different cellular contexts,
ROS are indicated to be essential signals to activate autophagy
stress by several stimulating conditions [205]. ROS appear
to be implicated in the regulation of autophagy through distinct mechanisms, depending on cell types and stimulation.
Autophagy, in turn, can reduce ROS production removing
ROS-overproducing organelles.
It seems that ROS, generated from both mitochondria
and NADPH oxidases, activate autophagy to protect cells
from nutrient starvation, dysfunctional mitochondria, cell
death, and invading pathogens [206]. The involvement of
ROS as signaling molecules in starvation-induced autophagy
was demonstrated for the first time showing that starvation triggered accumulation of ROS, most probably H2 O2 ,
which was necessary for autophagosome formation and the
resulting degradation pathway. The oxidative signal is partially dependent on phosphatidyl inositol 3 kinase (PI3K),
which plays a critical role in the early stages of autophagosome formation. Furthermore, a direct target for oxidation
by H2 O2 , the cysteine protease Atg4, has been identified
[207]. Whereas mitochondria were found to be involved in
starvation-induced autophagy [208], activation of antibacterial autophagy is due to NADPH oxidase that generates ROS
necessary for targeting of the autophagic protein LC3 to the
phagosome [205].
4.1.3. Autophagic and Apoptotic Cell Death. Autophagy usually promotes cell survival but when cellular damage is
pronounced and survival mechanisms fail, death programs
are activated in response to oxidative stress. The activation
of the autophagic pathway beyond a certain threshold has
recently been found to directly promote cell death by causing
the collapse of cellular functions as a result of cellular
atrophy (autophagic or type II cell death) [209]. This form
of autophagic cell death, which is necessary under certain
conditions, such as in apoptosis-defective cells [210], is
activated in response to oxidative stress in nervous cells, as
shown by oxidative stress and autophagic death induced in
human neuroblastoma SH-SY5Y cells [211] and sympathetic
neurons [212] by dopamine and growth factor deprivation,
respectively.
Autophagy can also lead to the execution of apoptotic or
necrotic (type III cell death) programs, likely via common
regulators such as proteins from the Bcl-2 family [196].
Apoptotic death is an adaptive process, allowing for renewal
of the organism constituents and life maintenance, which,
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differently from necrosis, is a form of cell death that causes
minimal damage to surrounding cells.
Apoptosis plays an important role in the elimination of
unnecessary, damaged, or diseased cells during the whole
lifespan and particularly during embryogenesis, when a
majority of newly formed cells undergo programed cell
death. Although both types of cell death have been linked to
autophagy, cell death does not necessarily result from a previous autophagic process. Depending on the cellular context
and death trigger, apoptosis and necrosis either cooperate in
a balanced interplay involving autophagy or are employed by
cells in a complementary way to facilitate cellular destruction.
A further complication results by the observation that apoptosis, necrosis, and autophagy are often regulated by similar
pathways, engage the same subcellular sites and organelles,
and share initiator and effector molecules.
An example is supplied by the cellular response to MPT
pore opening. This process provides a common pathway
leading to mitophagy, apoptosis, and necrosis [213]. With
low intensity stress, limited MPT leads to mitoptosis, which
is followed by the elimination of degraded mitochondria.
Recent studies have shown that removal can occur through
two different processes which rid cells of damaged mitochondria, the formation of mitoptotic bodies which are
then extruded from the cell [214] or selective autophagy
[215]. With increasing stress MPT involves an increasing
proportion of mitochondria and cellular response progresses
from mitoptosis to apoptosis driven by mitochondrial release
of cytochrome c and other proapoptotic factors. This event
occurs if permeabilization affects a great number of mitochondria, in the absence of excessive reduction in ATP levels,
and can purify tissue from cells that produce large amounts
of ROS [70]. Lastly, when extreme stress causes MPT pore
opening in virtually all cellular mitochondria, ATP levels
drop, and, because of bioenergetic failure, neither autophagy
nor apoptosis can progress, and only necrotic cell death,
which is not dependent on energy supply, ensues [197].
Another example involves cellular responses to ER stress,
which include the activation of UPR, autophagy, and cell
death [216]. These processes are not mutually exclusive, and
there is significant cross talk between these cellular stress
responses. Autophagy upregulation during ER stress is a prosurvival response directed to removal of unfolded proteins,
protein aggregates, and damaged organelles, which is triggered in order to relieve the stress and restore ER homeostasis
[217]. However, prolonged or unresolved ER stress results in
apoptotic program activation [218]. Sometimes, the effect of
autophagy on cell survival in ER stress also depends on the
tissue type. In colon and prostate cancer cells, ER-induced
autophagy protects against cell death, whereas in normal
colon cells autophagy does not alleviate ER stress but rather
contributes to ER-induced apoptosis [219].
Recent studies have shown several pathways that mediate
the interplay between autophagy and apoptosis providing
mechanistic insight into the network regulating both processes [220]. However, the mechanism by which ER stress
induces apoptosis is not fully delineated, even though it
is clear that mitochondria-dependent and independent cell
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death pathways can mediate apoptosis in response to ER
stress.
In ER-mitochondria-independent cell death pathway,
caspases are required for apoptosis, and some members
of this family of proteases are associated with the ER. In
rodents, caspase-12 is ER-membrane proapoptotic protease
specifically activated upon prolonged UPR. Several pathways
involve caspase-12 activation in cell apoptosis after ERinduced stress. A pathway triggers apoptosis by ER stressspecific caspase cascade leading to the caspase-9 and caspase3 activation in cytochrome c and apoptotic protease activating factor-1 (Apaf-1) independent manner [221].
ER stress can also trigger apoptosis by mitochondriadependent pathways [222] which can share actors with
mitochondria-independent pathways. The phosphorylation
of inositol-requiring enzyme 1 (IRE1) leads to the phosphorylation of c-Jun N-terminal kinase (JNK) that, in turn, can
activate p53 transcription factor. The p53-induced expression
of a protein, the Bcl-2 interacting mediator of cell death (Bim)
[223], leads to the formation of the BAX/BAK pore on the
outer mitochondrial membrane and cytochrome c release
resulting in activation of the canonical apoptosis pathway.
Whereas the relationship between mitochondrial oxidative stress and cell death is well-established [224], that of peroxisomes in cell death pathways is just beginning to emerge.
In light of the strong impact of peroxisome dysfunction on
mitochondria, it is possible that peroxisome-derived mediators of oxidative stress have an influence on mitochondria
that would have profound implications for cell fate.
In fact, it has been reported that excess ROS generated
inside peroxisomes quickly perturbs the mitochondrial redox
balance and leads to remarkable mitochondrial fragmentation [225]. In a recent study using targeted variants of the
photosensitizer Killer Red it has been showed that the phototoxic effects of peroxisomal Killer Red induce mitochondriamediated apoptotic death and that this process is inhibited
by targeted overexpression of antioxidant enzymes, including
peroxisomal glutathione S-transferase kappa 1, superoxide
dismutase 1, and mitochondrial catalase [226].
Over the last decades, the intricate molecular events
underlying the process of apoptosis have been elucidated
[227]. It is apparent that crucial steps involve mitochondrial
release of proapoptotic factors, although the exact mechanisms involved in this release are less well understood.
In this regard, it seems that, in some circumstances, the
release into the cytosol of lysosomal constituents may be an
initiating event in apoptosis and that mitochondrial release
of proapoptotic factors might be a consequence of earlier
lysosomal destabilization [228].
The destabilization of the lysosomal membrane is due
to its vulnerability to oxidative stress, because agents, which
induce oxidative stress, such as H2 O2 [229] and radiation
[230], also promote lysosomal membrane rupture. Different
cell types but also cells of the same type and lysosomes
of individual cells exhibit different lysosomal resistance to
oxidative stress [231]. It has been suggested that such a resistance mainly depends on the capacity to degrade H2 O2 before
it reaches the acidic vacuolar compartment, resistance to ROS
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of lysosomal membranes, and lysosomal content of redoxactive iron [231]. Lysosomal membrane permeabilization per
se triggers intracellular formation of ROS, a process which
can be mediated by the action of lysosomal proteases, such as
cathepsins B and D, which leak into the cytosol [208]. These
enzymes affect mitochondria inducing further cytochrome c
release and activation of caspase-mediated cell death [208,
228]. The involvement of lysosomes and their iron content in
radiation-induced cell death is supported by the observation
that cells are significantly protected from radiation damage if
exposed to iron chelators [163, 165]. Conversely, the involvement of lysosomal proteases in cell death is supported by
the observation that apoptosis inhibition by cyclosporin Ainduced block of MPT pore opening favors the development
of a necrotic form of cell death, which is attenuated by ROS
scavengers and inhibition of cathepsin D activity [232].

5. Harmful and Beneficial Effects of ROS
during Exercise
It is well documented that acute physical exercise can produce
significant damage, including alterations in membranes of
mitochondria and sarcoplasmic and endoplasmic reticulum
[233–236] in skeletal muscles and other tissues. The contraction form most damaging to skeletal muscle is that in which
the muscle is contracting while being lengthened (eccentric contraction). During such a contraction, disruption of
cytoskeletal structures, loss of muscle force generation, and
influx of phagocytic cells and neutrophils into the damaged
fibers occur [237].
Different from acute exercise, aerobic physical activity
regularly performed (training) induces adaptive responses
in the whole organism and particularly in the cardiorespiratory and musculoskeletal systems [238], which lead to an
increased ability to perform prolonged strenuous exercise
[235]. Moreover, it has several healthy effects, including
the maintenance of insulin sensitivity and cardiorespiratory
fitness, so that it is able to prevent type 2 diabetes [239]
and coronary heart diseases [240], and can also be used as
adjunctive therapy in the treatment of patients with diabetes
[241] and chronic heart failure [242].
To date, the idea that the opposite effects of acute exercise
and training are in great part due to the ability of ROS to play
a dual role in animal organisms is widely shared. In fact, it is
well documented that, during a single session of prolonged
aerobic exercise, ROS production increases and this can lead
to cellular damage and dysfunction. On the other hand, some
results suggest that the ROS produced during each session
of a training program can act as factors inducing cellular
adaptations to exercise.
During physical activity several ROS sources can be
activated contributing to the oxidative damage and/or to
the adaptive processes. It is reasonable to imagine that an
initial source of ROS can activate the ROS release from
other sources, inducing a positive feedback loop. In the next
sections, we will point out our attention to what is known
about production, sources, and double action of ROS during
acute exercise and training.

Oxidative Medicine and Cellular Longevity

6. Acute Exercise
6.1. ROS Production. ROS involvement in the tissue damage
found after prolonged aerobic exercise was suggested in the
late 1970s [243], but there is still no direct evidence that
ROS production increases during exercise. Electron spin
resonance (ESR) spectroscopy was able to furnish direct
information of the presence of free radical species, but
such a technique allows obtaining information on the ROS
production after exercise. Davies et al. [244] first reported
that signals of free radicals were enhanced in rat muscle
and liver after a bout of exhaustive running. Subsequently,
increased generation of free radical signals was observed
in rat heart after an acute bout of exhaustive endurance
exercise [245]. The idea that free radical activity might
increase after extensive muscular activity was also confirmed
on skeletal muscles subjected to electrical stimulation [246].
Using ESR spectroscopy in conjunction with the spin tapping
technique, enhanced free radical concentration in human
serum following exhaustive exercise was found [247, 248]
which was prevented by ascorbic acid supplementation [249].
Indirect information on ROS production during acute
exercise has been obtained by the changes in indexes of oxidative damage to lipids, proteins, and DNA and in the cellular
redox state. A plethora of information exists concerning the
increase in such indexes in various animal species, including
human, but here we focus our attention on what is available
in literature on rat.
Lipid oxidation can be evaluated measuring tissue levels of oxidized lipids, such as lipid hydroperoxides, or
those coming from their degradation, such as malondialdehyde (MDA) and 4-hydroxyl-2-nonenal. Numerous studies
showed increase in lipid oxidation markers in skeletal [244,
250–254] and cardiac muscle [251–253, 255], liver [244, 250–
254, 256], brain [257], erythrocytes [258], and kidney [254]
of untrained rats after acute exercise.
Exercise-induced increases in protein carbonyl content,
a marker of protein oxidative damage, were reported in rat
skeletal [253] and cardiac muscle [253, 255], liver [253, 256],
and plasma [259]. Furthermore, increases in 8-hydroxy-2 deoxyguanosine (8-OH-dG), a marker of oxidative damage to
DNA, were also found in rat skeletal [260] and cardiac [255]
muscle, liver, and lung [260] after acute exercise.
Some studies reported that the extent of oxidative damage
depends on duration or intensity of exercise. One such study
showed that exhaustive maximal exercise caused plasma
MDA increase while short periods of submaximal exercise
(less than 70% VO2max ) reduced lipid peroxidation [261].
Liver oxidative damage indexes did not change after 5 h of
swimming and increased after 8 h of exercise [192]. Another
study showed that an acute bout of a moderate as well as
high intensity exercise led to an increase in malonaldehyde
and lipid hydroperoxide levels in red vastus, white vastus,
and soleus muscle [262]. The study also showed that when
intensity of exercise was considerably decreased, lower MDA
levels were found [262].
Reduced glutathione (GSH), a thiol-containing tripeptide
playing a vital role in maintaining cells in the reduced
state and in protecting tissues from oxidative stress [263],
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is involved in reducing radicals arising from a variety of
antioxidants, such as 𝛼-tocopherol and ascorbic acid, to the
native structure [9]. GSH is oxidized to glutathione disulfide
(GSSG) donating a pair of hydrogen atoms. The ratio of
GSH to GSSG is used as an indicator of intracellular GSH
redox status. A decrease in GSH/GSSG ratio suggests that
the production of ROS goes over the reducing capacity of
GSH and other antioxidants. Therefore, change of GSH redox
status has been used as a footprint of oxidative stress during
exercise. Several studies showed that prolonged exhaustive
exercise promoted oxidation of GSH to form GSSG in the
blood [264], liver [253, 264], heart [253, 265], and skeletal
muscle [253, 264] of rats, even though it is possible that
the GSH redox state in the muscle is not altered by short
term exercise. Indeed, it was reported that physical exercise
at submaximal level determined a progressive depletion of
liver GSH to about 20% of the levels found in sedentary
rats which persisted for several hours following the cessation
of exercise [266]. However, skeletal muscle appeared to be
spared by this severe depletion phenomenon, whereas the
levels of plasma glutathione exhibited a transient increase
at the beginning of the exercise bout followed by a linear
decrease with increased running time [266]. In liver, the
early decrease in GSH level during exercise did not depend
on increased ROS production, even though it could be one
of the factors inducing liver oxidative stress. Evidence that
a decrease in liver GSH content precedes oxidative stress
was supplied by the finding that prolonged exercise led to
increased lipid peroxidation and decreased GSH content,
while exercise of shorter duration was not able to induce
oxidative stress in liver, although it reduced GSH content
[192]. The liver GSH reduction can be due to several factors. It
has been suggested that the exercise linked increase in plasma
levels of glucagon, vasopressin, and epinephrine stimulates
hepatic efflux of GSH which is delivered to tissues, such as
skeletal muscle that necessitates a larger tripeptide supply and
its uptake from the plasma [267, 268].
6.2. Sources of ROS during Physical Activity. Notwithstanding
most work indicates that exercise increases ROS production
in rat tissues, the debate about the cellular sources of such
ROS is still open. Several intracellular sources of free radicals
have been identified and it is possible that all contribute to
the increased ROS production during exercise even though
the extent of their contribution can depend on several factors
including the type of tissue and exercise.
Mitochondria, NADPH oxidase, and xanthine oxidase are
considered the main ROS sources during exercise but it is
necessary to point out that reports concerning other cellular
sources are scarce or lacking.
6.2.1. Mitochondria. Mitochondria were long considered the
main source of ROS in the cell during physical activity.
Initially, this belief stemmed from the widespread idea that
in tissue free radical production was closely related to oxygen
consumption [269]. Since over 90% of the oxygen consumed
by a mammal is utilized in the mitochondria, which appear
to generate free radicals in all tissues studied [270], it was
speculated that the increase in muscular oxygen consumption
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during exercise was associated with an increase in free radical
production by the respiratory chain localized in the inner
mitochondrial membrane [269].
During muscle contraction, ADP concentration increases
and stimulates mitochondrial oxidative phosphorylation
[271], shifting the mitochondrial respiration nearer to State
3 than to State 4 oxygen consumption. Therefore, the close
link between ROS production and O2 consumption should
require that the percentage of total electron flow escaping
from the respiratory chain to reduce O2 to superoxide radical
(the mitochondrial free radical leak) is not modified during
the transition from State 4 to State 3 happening during
muscle contraction. However, this idea is theoretically and
experimentally inconsistent. The rate of the mitochondrial
ROS generation is related to the degree of reduction of
electron carriers able to donate electrons to oxygen, and
such a degree of reduction decreases during transition from
State 4 to State 3 [272]. In agreement with such prediction,
measurements performed on isolated mitochondria show
that ROS mitochondrial release is higher in State 4 and in all
conditions when the rate of electron-transfer is lowered [272].
Nevertheless, results obtained measuring ROS release
from mitochondria isolated from tissues of animals that
exercised suggest that mitochondrial ROS release might
increase during prolonged aerobic exercise not only in muscle
but also in other tissues, such as liver and heart [272].
An increased release of ROS during basal and stimulated
respiration, with respiratory substrates linked to Complex
I (pyruvate plus malate) or Complex II (succinate), was
reported for mitochondria isolated from the muscles of
the hind limbs [273], gastrocnemius (red portion), heart,
and liver [253] of rats subjected to prolonged swimming.
Increased ROS release was also reported following prolonged
treadmill running [274] in heart mitochondria. The increased
ROS release was associated with an increase in the levels
of oxidative stress markers in mitochondria isolated from
cardiac and skeletal muscles and liver [253] of rats subjected
to prolonged aerobic exercise. It was also accompanied by
alterations in mitochondrial functionality. Indeed, exercise
increased State 4 respiration in liver, muscle [253], and heart
[253, 274] mitochondria and decreased State 3 respiration in
liver and muscle mitochondria [253]. Such results suggest the
possibility that, whatever the initial source of ROS during
exercise is, such ROS can damage mitochondrial components
inducing both functionality impairment and increasing ROS
release. It was initially proposed that the ROS formation
during exercise could involve the loss in the cytochrome
oxidase activity and a consequent increase in the electron
pressure within the respiratory chain [275]. The finding that
in hind limb muscle mitochondria exercise-induced change
in mitochondrial respiration is not associated with changes
in the cytochrome oxidase activity [273] seems to exclude
such a possibility suggesting that oxidative modifications of
other components of mitochondrial membrane are involved.
Oxidative modifications of lipids and proteins located in the
inner mitochondrial membrane could be responsible for the
increase in State 4 respiration. The increase in State 4 respiration rate represents a compensatory response to the increased
leak of protons back in the mitochondrial matrix. It has
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been proposed that adenine nucleotide translocase (ANT)
and uncoupling proteins (UCPs) are involved in proton
conductance of mitochondrial membrane [276]. However,
the observation that in skeletal muscle ANT expression is
not affected by acute exercise [277] excludes that ANT is
responsible for the increase in State 4 respiration induced by
exercise. Moreover, it is known that an uncoupling protein
1 (UCP1) catalyzes inducible proton conductance in brown
adipose tissue (BAT) [278], and exercise upregulates UCP1
homologue expression in skeletal [279] and cardiac muscle
[274]. However, whether in tissues differently from BAT
UCP1 homologues are responsible for mitochondrial basal or
inducible proton conductance is yet controversial [280].
More support is available for the idea that the observed
enhancement in State 4 respiration is due to high production
of ROS and RNS, which seem to be able to affect proton leak through an indirect mechanism. Both O2 ∙− [281]
and ONOO− [282] increase mitochondrial proton leak by
enhancing the extent of peroxidative processes [282, 283].
Therefore, it is conceivable that the increase in State 4 respiration induced by exercise may be due to a lipid peroxidationmediated increase in proton leak.
The decrease observed in State 3 respiration can be due
to a direct action of ROS and/or RNS. Indeed, damage to
respiratory chain components by ROS [284] and inhibition of
mitochondrial function by ONOO− [109] have been reported.
The decline of the respiration rate in mitochondria from rats
that exercised is likely to involve ONOO− , which during
exercise could be formed in greater amount and cause
irreversible inhibition of many mitochondrial components
different from cytochrome aa3 [285].
Inhibition of mitochondrial function and increase in ROS
release could also be due to the increase in mitochondrial
Ca2+ content, which occurs in skeletal muscle after prolonged
exercise [286] and leads to oxidative phosphorylation inhibition [287]. The Ca2+ effect on mitochondrial function results
from induction of mitochondrial permeability transition
(MPT) [114], which leads to degradation of the heaviest mitochondrial subpopulation characterized by high respiratory
capacity and susceptibility to Ca2+ -induced swelling [190].
Following long-lasting exercise, a transfer of damaged
mitochondria in the lightest fraction happened in rat liver,
as demonstrated by the increase in protein percent content
in such a fraction and its decrease in the heaviest one
[192], whereas a similar transfer did not happen in skeletal
muscle [273]. This agrees with the observation that acute
exercise enhances mitochondrial resistance to Ca2+ overload
in human skeletal muscle [277]. The Ca2+ tolerance of
mitochondria after exercise could be due to the maintenance
of relatively high levels of GSH, which should prevent mitochondrial membrane potential collapse [288] which precedes
MPT pore opening. Although this can appear as a protective
mechanism, it slows removal of ROS-overproducing mitochondria thus enhancing exercise-induced muscle oxidative
damage and dysfunction.
6.2.2. NADPH Oxidases. In the cells of skeletal muscle, the
isoform NOX2 is expressed [289] and protein subunits have
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been identified in transverse tubules and triads obtained
from rabbit skeletal muscle but not in sarcoplasmic reticulum
vesicles [290]. Some authors suggested that this is one of the
main sources of ROS during in vitro muscle contraction or
electrical stimulation [291, 292]. Moreover, it was demonstrated that muscle contraction increased O2 ∙− in cytosol and
subsequently in mitochondria, suggesting that NADPH oxidase could be a potential primary source of ROS production
during muscle contraction [293]. It is conceivable that during
muscular activity the increased activity of NADPH oxidase
can produce excessive ROS release which can contribute to
damage cellular components. However, it is also possible that
such a release can have beneficial roles. The increased level
of ROS induces changes in intracellular calcium levels which
are the result of oxidative modification of calcium channels or
other proteins involved in calcium signaling [294] and it has
been suggested that NOX2 ROS production may be necessary
for the excitation-contraction coupling process [290].
The mechanism of activation of NADPH oxidase has not
been completely defined but a recent paper suggests that this
can involve the increase in ATP release. Electrical stimulation
of adult muscular fibers isolated from the muscle flexor digitorum brevis activates a voltage gated L-type calcium channel
(Cav1.1) with each depolarizing event. This activation induces
ATP release via pannexin-1 (PnX1) channel which colocalizes
in the transverse tubules with Cav1.1 [295]. These events, in
turn, trigger a signaling cascade where, through ATP activation of a purinergic receptor (P2Y), phosphatidylinositol
3-kinase-𝛾 and phospholipase C and consequently protein
kinase C, which activates NOX2 oxidase and ROS release
[296], are activated. It is conceivable that a similar activation
can happen also in in vivo muscle because an increase in ATP
concentration has been found in the interstitial muscular
space after exercise and contraction [297, 298].
6.2.3. Xanthine Oxidases. Studies performed using XO inhibitors suggested a potential role of enzyme XO as a source
of oxidative stress, during ischemia-reperfusion in various
tissues, such as intestine, heart, lung, kidney, and liver [98,
299, 300]. In particular, XDH/XO activity in liver has been
reported to be relatively higher with respect to other organs
[301, 302]. On the other hand, it has been demonstrated that
liver blood flow during severe exercise may be reduced to
half of normal, indicating that exercise can induce ischemia
or hypoxia in the hepatic tissue [303]. These findings would
suggest that XO produces free radicals which may influence
the function of hepatic cells during and/or after strenuous
exercise. Furthermore, inosine and hypoxanthine produced
by the skeletal muscle during severe exercise have been
reported to be taken up by the liver via the blood stream and
oxidized to uric acid mainly after exercise [304]. According
to these observations, it was shown that the liver has a
substantially higher risk of oxidative stress following a single
bout of exhausting exercise, rather than during the exercise
itself [305].
It has been reported that xanthine oxidase produces O2 ∙−
in the contracting rat [306] and human skeletal muscles
[307]. However, there is controversy about the role xanthine
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oxidase plays in O2 ∙− production of human skeletal muscle during contraction, because such a muscle appears to
possess low amounts of xanthine dehydrogenase or oxidase
[308], even though these enzymes are present in associated
endothelial cells. It has been speculated that postexercise
oxidative stress in mouse skeletal muscles may be due to
the conversion of XDH into XO in capillary endothelial
cells [309] and enhanced adenosine 5 -triphosphate (ATP)
degradation together [310].
More recently, it was found that the administration of
allopurinol, XO inhibitor, did not prevent the increase in
protein and lipid oxidative stress markers in rat plasma,
erythrocytes, and gastrocnemius muscle due to swimming
exhaustion [311]. Moreover, in rats treated with allopurinol
alone, a similar increase in protein and lipid oxidative stress
markers in erythrocytes and gastrocnemius muscle was
found. The combination of allopurinol and exercise appeared
to increase protein oxidative damage in plasma and protein
and lipid oxidative damage in erythrocytes. Interestingly,
allopurinol provoked a marked reduction in physical performance as demonstrated by the 35% decrease in the swimming
time to exhaustion [311]. This result is in contrast with another
work reporting a lack of effects of allopurinol administration
on the time to exhaustion in rats performing treadmill
running [305]. The discrepancy can be due to the different
type of exercise and/or to the different doses of allopurinol.
However, it is interesting that notwithstanding allopurinol
seems to have intrinsic antioxidant properties being a potent
hydroxyl radical scavenger [312, 313], it either did not change
or decreased the time to exhaustion, differently from what
was found administering antioxidants before an exhaustive
exercise [314].
Another study [315] reported that, following acute
exercise (60 min treadmill running 27 m/min, 5% incline),
skeletal muscle oxidized glutathione (GSSG) significantly
increased in allopurinol- and vehicle-treated rats despite XO
activity and uric acid levels were unaltered. This suggests that
XO was not the source of ROS during exercise. In the whole,
the available data obtained by XO inhibition suggest that the
enzyme can be a source of ROS during exercise but not the
main.

7. Training
7.1. Effects of Training on Tissue Oxidative Damage. Contrary to acute exercise, aerobic exercise training induces
adaptations which reduce liver [316] and skeletal [317] and
cardiac muscle [318] oxidative damage of lipids and proteins.
Such adaptations also render tissues less susceptible to the
oxidative damage induced by conditions leading to oxidative
damage. Indeed, training attenuates lipid and protein oxidative damage and glutathione depletion in rat heart subjected
to ischemia-reperfusion [319]. Moreover, training prevents
lipid peroxidation increase induced by moderate intensity
exercise in rat liver and muscle [250]. However, other studies
suggested that training does not affect the extent of lipid
peroxidation due to exhaustive swimming but, delaying the
rate of the peroxidative reactions, allows trained animals to
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sustain the activity for a longer period before the fatigue
becomes limiting [251, 252].
It is clear that training exerts protective effects reducing
oxidative damage of tissues and increasing their resistance
to oxidative challenges. Such effects seem to be associated
with increased cellular antioxidant defenses. Several studies
examined the effect of training on the activities of antioxidant
enzymes. Much of these studies may not be directly compared
to each other because of the differences in experimental
design, animal model, and analytical procedures. However,
in the whole they show that training results in an increase
in skeletal [320] and cardiac [321] activity of antioxidant
enzymes, such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, even though some
studies failed to find enhanced antioxidant activity after
training.
The training effect on liver antioxidant enzymes has
been less studied and the results are rather contrasting. On
the other hand, it was previously reported that liver total
antioxidant capacity was increased by training as well as those
of skeletal and cardiac muscle [251, 252].
Surprisingly, there are few studies concerning the effect
of training on antioxidant enzyme expression. However,
increases induced by training in CuZnSOD mRNA abundance in rat liver and heart [322] and Cu, ZnSOD, and
MnSOD protein level only in some muscles but not in others
[322, 323] were reported.
It is likely that training exerts its protective effects also
decreasing H2 O2 production, even though scarce information is available on training impact on cellular ROS sources.
The rate of H2 O2 release was decreased in liver [316], skeletal
muscle [317, 324], and heart [318] mitochondria from rats
trained to swim and in heart mitochondria [325] from rats
trained to run. Conversely, no effect on H2 O2 release was
found in skeletal muscle mitochondria following voluntary
wheel training [326].
Measurements of H2 O2 release rate in the presence of
respiratory inhibitors suggested that training reduces the
concentration of the autoxidizable electron carriers located
at Complexes I and III in the liver [316] and muscle [317]
mitochondria and that of the autoxidizable electron carrier
located at Complex III in the heart mitochondria [318].
However, other swim training-induced adaptations can contribute to the reduction of the H2 O2 release rate found in
the mitochondria isolated from liver heart and muscle. These
could include the increased activity of the H2 O2 metabolizing
enzyme GPX, which is coupled with the increase in GR
activity, in the mitochondria of the three tissues [316–318].
Conversely, it is unlikely that the decrease in H2 O2 release
is due to increased uncoupling of the inner mitochondrial
membrane, since that training reduces mRNA expression
of uncoupling protein 3 in skeletal muscle and uncoupling
protein 2 in skeletal and cardiac muscles [327].
The effects of exercise training on NADPH oxidase activity are limited but some data suggest that exercise training
is able to modulate NADPH oxidase activity. For example, it
has been reported that exercise training mitigates age-related
upregulation of NOX2 subunits gp91phox and p47phox in rat
heart [328], reduces microvascular endothelial NOX content
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in muscle biopsies from vastus lateralis of obese men [329] but
not of lean men [330], and downregulates NADPH oxidase
expression in obese rats [331]. Studies using XO inhibition by
allopurinol show that such an inhibition produces complex
effects that are not yet fully elucidated so that the relative
data are not conclusive and do not allow us to point out
the relevance of the ROS produced by XO for the training
adaptations.
7.2. Mitochondrial Biogenesis. The improved cardiovascular
function and aerobic capacity elicited by aerobic exercise
training require an increased tissue metabolic activity. The
first proof that the increase induced by the training in
metabolic capacity was due to the increased tissue mitochondrial protein content was obtained in the skeletal muscle
[332, 333]. Subsequent studies confirmed this finding [317]
and showed that swim training increased mitochondrial
protein content also in other tissues such as liver [316]
and heart [318]. However, the changes in mitochondrial
protein content seemed to differ in various tissues and
were associated with different changes in the metabolic
capacity of tissues and mitochondria. Indeed, in the skeletal
muscle swim training increased tissue metabolic capacity by
inducing a moderate increase in the tissue content of the
mitochondrial population characterized by a lightly reduced
aerobic capacity [317]. In liver, swim training did not induce
increases in tissue metabolic capacity because the modest
increase in mitochondrial population content was balanced
by the reduction in mitochondrial metabolic capacity [316].
In heart, swim training increased tissue metabolic capacity
by enhancing lightly both mitochondrial population content
and mitochondrial respiratory capacity [318]. These different
responses are consistent with the different functions of liver
and muscles as energy supplier and consumers, respectively
[334], during aerobic long-lasting exercise.
7.3. Mechanisms of Adaptive Response to Exercise. Mitochondrial biogenesis requires that expression of the mitochondrial
genome and nuclear genes encoding mitochondrial proteins
is finely organized. The process is controlled by the peroxisome proliferator-activated-receptor-gamma coactivator
1 (PGC-1) which regulates the expression of transcription
factors such as nuclear respiratory factors 1 and 2 (NRF-1 and
NRF-2) [335]. NRF-1 and NRF-2 control the expression of
many genes, among which are those implicated in mitochondrial biogenesis, adaptive thermogenesis, glucose and fatty
acid metabolism, fiber type switching in skeletal muscle, and
heart development [336].
PGC-1 expression increases quickly in muscle cells stimulated to contract [337], in rat skeletal muscle after a single
bout of exercise [338] and in human skeletal muscle after
endurance training [339]. A study using PGC-1𝛼 knockout
mice showed that in liver PGC-1𝛼 plays a pivotal role in
regulation of cytochrome c and cytochrome oxidase subunit
I expression in response to a single bout of treadmill exercise
and prolonged exercise training, which suggests that the
exercise-induced changes in tissue oxidative capacity are
regulated by PGC-1𝛼 [340].
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Increases in PGC-1𝛼 expression were also found in heart
after short term training to treadmill run [341] and in liver
[316], skeletal muscle [317], and heart [318] after 10 weeks
of training to swimming. In these tissues, the increases in
PGC-1𝛼 expression were associated with an increase in the
expression of NRF-1 and NRF-2.
Interestingly, in addition to regulating mitochondrial
biogenesis, PGC-1 is able to regulate endogenous antioxidant
expression, such as Cu, ZnSOD, MnSOD, and GPX, in skeletal muscle [342, 343]. This coordination of the proliferation of
ROS producing organelles with increase in antioxidant levels
likely helps to maintain redox homeostasis. In addition, it has
been shown that PGC-1𝛼 promotes mSIRT3 gene expression,
which is mediated by ER-binding element mapped to the
SIRT3 promoter region [344]. In turn, SIRT3 binds to, deacetylates, and activates mitochondrial enzymes, including
MnSOD, through a posttranslational mechanism [345].
PGC-1𝛼 is also able to regulate the mRNA expression of
uncoupling proteins 2 and 3 in cell culture [346], suggesting
that PGC-1𝛼 may also increase the uncoupling capacity and
concomitantly reduce ROS production in the mitochondria
[343].
Several initiating stimuli, activated during exercise, can
contribute to eliciting the PGC-1 gene response. These
include (i) increase in cytosolic calcium concentration, which
activates various signaling pathways regulated by the calcineurin phosphatase and the calmodulin-modulated kinase,
(ii) the decrease in levels of high-energy phosphates, leading
to the activation of the AMP-sensitive kinase (AMPK), and
(iii) stimulation of the adrenergic system, leading to cyclic
AMP synthesis, and activation of protein kinase A and other
kinases, such as mitogen-activated protein kinase (MAPK)
[342]. However, it is necessary to point out that PGC-1𝛼
regulation is not only due to variation in expression but
also caused by covalent modifications among which are
phosphorylation, acetylation methylation, and ubiquitination. Indeed, in vitro experiments showed that p38 MAPK
and AMPK phosphorylate PGC-1𝛼 producing a more active
protein [342].
It seems that PGC-1 expression is also upregulated by
ROS. Indeed, the observation that antioxidant incubation
prevents the increase in PGC-1𝛼 mRNA induced by electrical
stimulation in rat skeletal muscle cell culture [347] indicates
that increases in ROS may contribute to exercise-induced
increases in skeletal muscle PGC-1𝛼 mRNA content. Thus,
the observation that the H2 O2 -induced increase in the mRNA
content of SOD, catalase, and GPX in PGC-1𝛼 KO fibroblasts
is lower than that in wild type fibroblasts [348] indicates a role
of PGC-1𝛼 in the upregulation of ROS removing enzymes in
response to increases in ROS.
Moreover, notwithstanding conflicting results exist in
literature [349], it was reported that antioxidant supplementation attenuates the PGC-1𝛼 expression increase due to
training [316–318, 350–352]. It was also reported that vitamin
E supplementation prevents the increase in activator and
coactivator levels and mitochondrial population adaptation
to physical training [316–318]. These results suggest that the
ROS produced during each session of exercise training are
able to regulate cellular functions acting as signals regulating
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molecular events crucial for adaptive responses of liver, muscle, and heart.
The role of ROS as signaling molecules in the tissue
adaptation induced by training seems to contrast with the
oxidative damage and dysfunction elicited by acute exercise.
However, this can be explained by differences in extent
and temporal pattern of ROS generation. Thus, a moderate,
intermittent ROS production during short time periods in
a program of graduate aerobic training can activate signaling pathways leading to cellular adaptation and protection
against future stresses. In contrast, moderate levels of ROS
production over long time periods (e.g., hours) or high levels
produced during brief exercise at high intensity may result in
structural and functional tissue damage.

8. ROS Production and Type 2 Diabetes
Type 2 diabetes and other related diseases, such as metabolic
syndrome and coronary heart disease, are a serious problem worldwide [353]. Specifically, diabetes is very closely
related to microvascular and macrovascular complications
that seriously affect the quality of life and life expectancy
of patients. At present, there are around 350 million people
worldwide with diabetes, a figure that will rise to 500–600
million over the following years. Diabetes, insulin resistance,
and cardiometabolic diseases are associated and constitute an
active field of research [354, 355].
Mitochondria are known to produce ATP after metabolization of nutrients and are capable of generating energy.
In this sense, it has been demonstrated that mitochondrial
dysfunction is characterized by decreased levels of ATP,
inhibition of mitochondrial O2 consumption, enhanced ROS
production, a decrease in the antioxidant content, and alterations in mitochondrial membrane potential (ΔΨ𝑚 ). These
effects are due mainly to an imbalance between energy intake
and expenditure [356]. In fact, a decrease in the activity of
the electron transport chain (ETC) complexes or increased
uncoupling produced by the activity of uncoupling proteins
or the ADP/ATP translocator (also called adenine nucleotide
translocase, ANT) can induce changes in ΔΨ𝑚 that eventually
lead to apoptosis [354, 355].
Different factors, both genetic and environmental (diet,
exercise, and stress), have been shown to modulate mitochondrial function and alter insulin sensitivity [357, 358]. In
this context, the presence of mitochondrial impairment has
been demonstrated in different types of leukocytes [359] and
tissues such as liver, lung, skeletal muscle, spleen, or heart
in type 2 diabetes [360, 361], confirming the relationship
between this condition and mitochondrial dysfunction.
Mitochondria are the main source of reactive oxygen
species (ROS), as mentioned previously. ROS are key to
the development of diabetic complications [362–364], and
studies have demonstrated that the use of antioxidants
such as lipoic acid (LA) can reduce insulin resistance and
ROS production (by improving mitochondrial function) and
prevent CVD in humans [365]. Recently, Faid et al. have
demonstrated that resveratrol can alleviate diabetes-induced
apoptosis by modulating caspase-3 activities, oxidative stress,
and JNK signaling [366].
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Electron transport chain (ETC) dysfunction is directly
related to diabetes and its complications, including retinopathy, nephropathy, and neuropathy [355]. Furthermore, some
studies have documented that deleterious genetic mutations
related to a reduction in the activity of Complex I can lead
to mitochondrial impairment and enhanced ROS production
[367]. Therefore, mitochondria-targeted antioxidant therapy
has been proposed as a beneficial tool in the treatment of
mitochondria-related diseases [368].
Victor’s group has performed several studies of type 2
diabetes patients which have shown that oxidative stress
and mitochondrial dysfunction occur due to a decrease in
O2 consumption, Complex I activity, membrane potential,
and glutathione levels and an increase in ROS production
[359, 369–371], thus confirming mitochondria as a key target
for diabetes treatment. In other related pathologies, such
as polycystic ovary syndrome (PCOS), in which patients
can develop insulin resistance, there is also an impairment
of mitochondrial Complex I and an increase in leukocyteendothelium interactions [372]. This mitochondrial dysfunction increases ROS production, reduces ATP and Ca2+ ,
and alters membrane potential and mitochondrial morphology. However, in an animal model of diabetes (db/db
mice), mitochondrial and renal function are improved in
the presence of mitochondria-targeted antioxidants, such
as CoQ10, highlighting the crucial role of mitochondria in
the development and pathogenesis of diabetic nephropathy
[373]. In addition, Victor’s group has demonstrated that
mitochondrial dysfunction and, especially, mitochondrial
ROS production are related to the development of silent
myocardial ischemia and endothelial dysfunction due to
increased leukocyte/endothelium interactions [374].
Mitochondria-targeted antioxidants have been shown to
have beneficial effects on conditions of oxidative stress. In
this sense, MitoQ is an antioxidant which, due to a covalent
attachment to the lipophilic triphenylphosphonium cation,
is selectively taken up 1000-fold by mitochondria [363, 375].
Chacko et al. demonstrated an example of the beneficial
effects of MitoQ on diabetes when they reported that MitoQ
decreased urinary albumin levels to the same level as those of
nondiabetic controls in a mouse model of diabetic nephropathy (Ins2(+/)-(AkitaJ) mice) [376]. Furthermore, glomerular
damage and interstitial fibrosis were significantly reduced in
the treated animals, and there was a nuclear accumulation of
the profibrotic transcription factors 𝛽-catenin and phosphoSmad2/3, which was prevented by MitoQ treatment. These
results support the hypothesis that mitochondrially targeted
therapies could be beneficial for the treatment of diabetic
nephropathy.
8.1. Insulin Resistance and Mitochondrial Dysfunction. Glucose homeostasis is regulated by insulin. In addition, insulin
has important cardiovascular, renal, and neural functions,
which may explain why insulin resistance is a risk factor for
microvascular complications such as retinopathy, nephropathy, hypertension, and CVD [25].
A series of conditions are related to the development
of insulin resistance, such as obesity, changes in lipid and
glucose metabolism, chronic inflammation, stress, or other
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oxidative factors. In these conditions, the appearance of
insulin resistance is frequently associated with a diminished
capacity of tissues or cells to respond to levels of insulin [377].
This process is related to mitochondrial dysfunction, changes
in mitochondrial dynamics, and enhanced ROS production.
In relation to this theory, it has been demonstrated that
mitochondrial impairment, oxidative stress, excess energy
intake, and lipodystrophy can enhance circulating free fatty
acids (FFAs), which can lead to the accumulation of triglycerides, FFAs, and diacylglycerol (DG) in different tissular
locations, including liver, skeletal muscle, heart, kidney, and
𝛽-cells. Furthermore, alterations in cholesterol subfractions,
such as an increase in the atherogenic potential of small dense
LDL, may be related to several metabolic properties of these
particles, facilitating their transport into the subendothelial
space [378], reducing LDL receptor affinity [379, 380], and
increasing susceptibility to oxidative modifications [378, 381].
The cited studies feed into the idea that small dense LDL
are related to arterial damage in patients with dyslipidemia
associated with diabetes.
Insulin resistance, mitochondrial dysfunction, and enhanced production of ROS, which act as secondary messengers by activating serine kinases that phosphorylate IRS
proteins, modulate the insulin response [377]. In addition,
ROS can trigger the inflammatory process by activating
IKKb, which phosphorylate IRS-1 [382]. Several studies
have demonstrated that insulin sensitivity and mitochondrial
function can be modulated by antioxidants, with a subsequent decrease in ROS production and an increase in the
expression of UCP2/3 and a decrease in ROS levels [382].
However, the results of the said studies have generated some
controversy [383].
Mitochondrial impairment and insulin resistance have
also been shown to be related to diminishing levels of mitochondrial oxidative enzymes, which reduce mitochondrial
complex activity, alter mitochondrial morphology, and limit
mitochondrial number [384]. For example, mitochondrial
oxidative capacity can correlate negatively with insulin sensitivity after the accumulation of intramyocellular lipids [385].
During obesity, there is an increase of triglycerides
in adipose tissue, and consequently glucose metabolism is
altered in other nonadipose tissues. In this sense, it has been
speculated that lipodystrophy induces insulin resistance,
mitochondrial dysfunction, and type 2 diabetes [386]. In
diabetes and obesity, adipocytes can release high amounts of
adipokines, such as resistin, leptin, adiponectin, and TNF-𝛼,
which can regulate metabolic pathways [387]. Furthermore,
the number and morphology of mitochondria, as well as the
expression of genes involved in mitochondrial biogenesis,
are significantly decreased by the energetic alterations that
appear as a result [388]. All of these studies support the idea
that insulin resistance is present in lipodystrophy, obesity,
and type 2 diabetes. This action leads to the accumulation of
intracellular fatty acid metabolites (e.g., diacylglycerol, fatty
acyl CoAs) in muscle and liver, which triggers the activation
of a serine kinase cascade and finally induces defects in
insulin signaling and insulin action in these tissues [389].
Oxidative stress, mitochondrial-endothelial dysfunction,
and insulin resistance are very common in cardiovascular
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diseases such as stroke, silent myocardial ischemia, coronary
artery disease, or hypertension [390]. In this sense, type 2 diabetic patients exhibit high blood pressure, whose appearance
is related to hyperglycaemia [391]. In relationship to this idea,
Katz et al. have highlighted that diabetes is associated with
a higher prevalence of calcified atherosclerotic plaque in the
thoracic arteries [392]. Furthermore, endothelial impairment
has been associated with intramyocardial lipid accumulation
and glucose intolerance and, eventually, heart failure [393].
Not all organs are specifically protected against oxidative
stress. For example, the heart, which has a high metabolic rate
and high beta oxidation and ROS production, contains low
levels of antioxidants, making it particularly susceptible to
oxidative stress, mitochondrial dysfunction, and subsequent
structural and functional abnormalities [394].
Mitochondrial oxidative stress damage and changes in the
morphology/function of mitochondria have been reported in
an animal model of obesity, namely, insulin-resistant obese
Zucker rats [395]. Obesity and lipotoxicity can also enhance
mitochondrial damage during the development of diabetic
retinopathy [396]. Experiments involving transmission electron microscopic analysis of myocardial tissue have demonstrated an increase of abnormal mitochondria in an insulinresistant rat model [397]. Another study showed an increase
in the number of mitochondria in hypertrophied rat hearts
under oxidative stress conditions [398]. In disagreement
with these studies, others have failed to find changes in the
number of mitochondria and their DNA content, while some
have even reported reduced numbers in patients and animal
models of pathological hypertrophy [399]. In conclusion,
these results point out the importance of mitochondria in the
heart and would suggest that they enhance CVD, including
heart failure, stroke, cardiomyopathy, coronary heart disease,
silent myocardial ischemia, and hypertension.
Insulin resistance is related to endothelial dysfunction
[400], but the underlying mechanisms are yet to be confirmed. In the endothelium, mitochondria play an essential role by acting as sensors of local alterations in the
concentration of O2 and as regulators of intracellular Ca2+
concentrations [401]. Taking into account that mitochondrial
dysfunction is related to endothelial dysfunction, different
studies have demonstrated that blockade of ROS generation
can improve endothelial function under hyperglycemia conditions [362, 402].
It is generally recognized that endothelial nitric oxide
synthase (eNOS) plays a key role in the maintenance of
vascular tone and insulin-stimulated NO∙ production in the
endothelium [403]. In fact, poor eNOS activity has been
related to insulin resistance, hypertension, and dyslipidemia
[404]. Therefore, there is an impairment in the NO∙ production under insulin resistance conditions, which is related to
the appearance of CVD such as coronary artery disease, heart
failure, stroke, or silent myocardial ischemia.
Insulin-resistant patients can develop type 2 diabetes
when there is impairment in 𝛽-cells, the result of which is an
incapacity to sense glucose properly and release insulin and
failed glucose homeostasis. In this sense, mitochondrial activity can modulate the potassium channels (𝐾ATP ) modulating
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ATP/ADP ratio. 𝛽-cell function and mitochondrial function
are related through the ATP/ADP ratio [405]. Furthermore,
mitochondrial Ca2+ levels are crucial to the maintenance of
insulin secretion, as demonstrated by Han et al. who showed
that taurine can enhance the glucose sensitivity of UCP2overexpressing 𝛽-cells, probably by enhancing mitochondrial Ca2+ influx and subsequently increasing the ATP/ADP
ratio and mitochondrial function [406]. Other studies have
highlighted the importance of mitochondrial function in
glucose homeostasis by using knockout Tfam (Transcription
Factor A, Mitochondrial) mice, Tfam being a nuclear DNAencoded mitochondrial protein, which results in a dramatic
mtDNA depletion, a decreased of insulin secretion, reduced
𝛽-cell mass, and the development of diabetes [407]. In
conclusion, all of the abovementioned studies highlight the
fact that preserving mitochondrial function is essential for
𝛽-cell function under oxidative stress conditions and that
mitochondrial impairment contributes to the pathogenesis
of type 2 diabetes by interfering with insulin action and
secretion. Furthermore, high levels of fatty acids can induce
mitochondrial dysfunction and impair insulin signaling due
to oxidative stress and enhanced ROS production. In summary, we consider that mitochondria should be considered
a key target in therapy for insulin resistance in general and
diabetes in particular.
Finally, we would like to mention that the possible
beneficial effects of RNS and ROS can occur at low levels and
can exert different physiological functions. Cells can produce
H2 O2 , O2 ∙− , or NO∙ at physiological levels, but, in the case of
diabetes, basal levels of ROS are elevated, and so these ROS
and RNS are generally harmful. For example, in basal conditions, leukocytes kill pathogens by phagocytosis after which
ROS are released. Basal levels of ROS can also trigger energy
production by mitochondria, induce mitogenic responses,
or activate the release of cytokines or nuclear transcription
factors.
NO∙ can also modulate vascular pressure, leukocyte
adhesion, and angiogenesis. Furthermore, NO∙ is an important neurotransmitter and is a key mediator of the immune
response when generated by activated macrophages.
Although different studies suggest that ROS act as secondary
messengers, it is clear that they can be harmful when they
accumulate and disrupt molecules and tissues [12, 408–410].

9. ROS and Neurodegeneration
The brain is composed of two main types of cells: glia and
neurons. Glial cells encompass a wide variety of cells including astrocytes, microglia, and oligodendrocytes. Glia cells act
as a neuronal support system and are the most abundant cells
in the nervous system. Astrocytes support neurons in the
brain and regulate the chemical and extracellular environment. They maintain low levels of ammonia and glutamate
and produce neuroprotective enzymes. Upon activation,
astrocytes repair cellular damage, mount an inflammatory
response, and activate microglia. Microglia, the smallest
glial cells, repair damage due to injury via phagocytosis. Oligodendrocytes are responsible for axon myelination,
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a protective layer required for propagation of action potentials and maintenance of intracellular communication.
Neurons (nerve cells) are the basic structural elements of
the nervous system. Their primary function is to transmit and
receive information through nerve impulses, electrochemical
signals that travel down the neuron. Neurons “sense” changes
in environmental conditions and respond to such changes
via neurotransmission. Neurons consist of three major components: the axon, dendrite, and perikaryon (or soma). The
axon, typically ending at a specialized structure called the
synapse, carries impulses to distant locations. The dendrite
acts as the neuronal “receiver” but can also communicate
via neurotransmitters to adjacent neurons. Dendrites become
denser during neurogenesis. Small dendrites do not contain
organelles, but large dendrites have neurofilaments (only
found in neurons), microtubules, ribosomes, and endoplasmic reticulum. The perikaryon is the “metabolic hub” of the
neuron. It houses mitochondria, ribosomes, Golgi apparatus,
and endoplasmic reticulum, essential machinery in protein
synthesis and energy production. Neurons are essential in
contributing to emotions, perceptions, and memory and
learning. Neuronal damage can alter these functions and
ultimately lead to overall brain dysfunction and decline in
the cognitive functions previously described. Neurodegeneration, an example of neuronal damage, is the loss of neuronal
structures or function. During the aging process, myelin
and neuronal loss occur, dendritic length and branching are
decreased, and global brain volume is reduced. Consequences
of these events include but are not limited to age associated
cognitive decline, memory loss, epigenetic changes, reduced
autophagy, and synaptic plasticity. Excessive neuronal death
resulting in accelerated cognitive decline and memory loss
has been observed in those suffering from neurodegenerative
disorders. Recent findings from Villeda demonstrated a
significant improvement in hippocampal learning exercises
and contextual fear conditioning tasks when old mice were
given plasma from young mice [411]. Other findings from
this study showed an increase in dendritic spine number and
synaptic plasticity in the old mice associated with reversal of
cognitive decline.
Astrocytes are highly abundant throughout the central
nervous system. Due to their extension-like end feet, they
cover the free surfaces of neuronal dendrites and soma.
Astrocytes also cover the inner surface of the one of the
brain’s most important meningeal membranes, the pia mater,
and all blood vessels in the CNS. More importantly, these
end feet surround the brain’s capillary endothelial cells of
the blood-brain barrier. They participate in neurotransmitter
metabolism and play a pivotal role in glutamate uptake
to prevent excitotoxicity. Glutamate is then converted into
glutamine via glutamine synthetase, in which the basic
amino acid is transported into the neuron. Furthermore,
astrocytes maintain the pH of the extracellular space and
ionic environment. In neurodegeneration, these cells can
release cytokines which regulate the inflammatory response.
Microglia act as macrophages in the brain. Phenotypic
characteristics include short spiny projections, which become
enlarged under ROS conditions. Neurodegeneration is a
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key promoter of microglial activation; therefore this phenomenon is observed in neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic
lateral sclerosis, and Huntington’s disease [412]. Microglia
also play a role in generating reactive nitrogen species as
nitric oxide synthases, iNOS and NOX2, and NADPH oxidase
are induced in these glial cells [413]. This NOX2 activation
can lead to a respiratory burst of superoxide flooding the
mitochondria further contributing to neurodegeneration.
In addition to their inflammatory response, microglia also
express multiple ion channels, namely, the sodium, proton,
voltage gated Ca2+ and Cl− , and potassium channels. Changes
in ionic concentrations may play a role in depolarization and
action potential initiation, which can trigger inflammation
and neuronal activation.
Activation of these glial cells can have dramatic cellular
effects including prompting an inflammatory response. This
occurs in the normal aging process due to mitochondrial
derived ROS production, which promotes inflammation
and cytokine production [414]. This consequence can be
observed as cognitive deficits as NF𝜅-B is generated and
neuroinflammation occurs. NF𝜅-B serves as a proinflammatory agent and a prosurvival molecule by regulating the
inflammatory response. This is an age-dependent process.
If the NF𝜅-B pathway is blocked in old mice, a reversal
of gene expression occurs [415]. Interestingly, NF𝜅-B is
highly associated with RNS as this family of proteins induces
nitric oxide synthase, further promoting nitrosative stress.
Prostaglandin synthesis is also initiated through the NF𝜅B signaling cascade, propagating the inflammatory process.
Neuroinflammation can be defined as the increased production of a multitude of proinflammatory molecules, mostly
notably interleukin-1𝛽 (IL-1𝛽), tumor necrosis factor 𝛼 (TNF𝛼), and transforming growth factor 𝛽 (TGF-𝛽). IL-1𝛽 is
a proinflammatory agent that recruits neutrophils as part
of the inflammatory response. This cytokine is frequently
observed in several neurodegenerative disorders [416]. TNF𝛼 is a key regulator of the immune system. It has been
shown to be increased in microglia from aged mice in
a lipopolysaccharide induced mouse model [417]. TNF-𝛼
is found predominantly in macrophages. It is released by
activated microglia and astrocytes which perpetuates neurodegeneration and neuroinflammation by increasing levels
of reactive oxygen species, specifically superoxide. The more
the neuronal damage, the more frequent the neuroinflammation as microglia and astrocytes are constantly activated.
In addition to the inflammatory properties of TNF-𝛼, it
directly activates NADPH oxidase which increases levels of
superoxide in the cells similar to NF𝜅-B. NOX2 is highly
expressed via TNF-𝛼, which is linked to excess levels of RNS
[418]. TGF-𝛽 regulates neuroinflammation and apoptosis by
releasing inflammatory cytokines and reactive oxygen species
[419]. TGF-𝛽 is mediated by the Smad3 pathway, which
inhibits the production of free radicals which are normally
promoted in the inflammatory pathway. This pathway is
impaired during neurodegeneration and could contribute to
the disease progression as neuronal loss and neuroinflammation are observed [420]. As these cytokines have been
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tested as biomarkers of oxidative stress, a link between ROS,
neurodegeneration, and neurodegenerative disorders can be
further bolstered.
Oligodendrocytes. Oligodendrocytes are vulnerable to oxidative damage as they have a higher ATP requirement than
other glial cells, contain low levels of glutathione, a potent
antioxidant, and have a high intracellular iron level which can
form prooxidants through Fenton chemistry [421]. The main
function of oligodendrocytes is myelination. The myelin
sheath is a necessary axonal component that increases saltatory conduction of action potentials, thereby stimulating
neurotransmission. Demyelinating disorders such as multiple
sclerosis exhibit motor function decline due to disruption of
action potential propagation from the loss of myelin.
It has been well-established that, in neurodegenerative
disease, neurodegeneration can occur as the result of oxidative stress, the imbalance of antioxidant and prooxidant levels
[422]. Reactive oxygen species levels increase as a function
of age and are even higher in age-related neurodegenerative
disorders [423]; therefore oxidative stress can also occur if
there is an excess of ROS/RNS production or an antioxidant
deficiency [424]. This section of the review will focus on
the interconnection between oxidative stress, reactive oxygen
and nitrogen species, and neurodegeneration in the aforementioned cellular systems and research directed at neuroprotection, the delay or prevention of neurodegeneration.
9.1. Oxidative Stress. Mitochondria are the key source for free
radicals [425, 426]. A minute amount of electrons leaks from
the mitochondria and reacts with molecular oxygen to form
superoxide. Other sources for free radicals can include environmental toxins [427], metal catalyzed reactions, certain
enzymatic reactions (e.g., xanthine/xanthine oxidase), and
cellular processes. During phagocytosis, oxidants are needed
to ingest bacteria, viruses, and other pathogens [428].
9.1.1. Hypochlorous Acid. Hydrogen peroxide can react with
a chloride anion to form hypochlorous acid (HOCl) via
myeloperoxidase (MPO). Myeloperoxidase is largely present
in neutrophils [429] but has also been located in neuronal
cells under certain conditions [430]. Hypochlorous acid can
further react with nitrogen dioxide (NO2 ∙ ) to form nitryl
chloride (NO2 Cl), a potent chlorinating and nitrating oxidant
[431]. Phagocytes use HOCl as one of their agents [432].
Hydrogen sulfide (H2 S) is an inhibitor of HOCl from Cl− .
Myeloperoxidase in the presence of H2 O converts Cl− into
Cl+ ; therefore hydrogen sulfide may have a protective effect.
H2 S levels are lowered in Alzheimer’s disease, a neurological
disorder [433]:
MPO

H2 O2 + Cl− → HClO

(3)

9.1.2. Reactive Nitrogen Species. Similar to ROS, reactive
nitrogen species are highly toxic [434]. Some examples of
RNS, nitric oxide, and nitrogen dioxide will be discussed
below. Reactive nitrogen species cause protein nitration by
various methods, which can result in protein dysfunction and
neuronal loss.

NO∙ has been shown to play a role in neurodegenerative
diseases by acting as a neurotoxin when excessively produced
[435]. Hara has shown that glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) acts as NO∙ sensor [436]. NO∙ is
involved in cell signaling pathways immune response and
vasodilation. NO∙ activates protein kinase C (𝜀 isoform),
which activates a specific family of tyrosine kinases that can
stimulate apoptosis [437]. NO∙ can also bind to glutamate
channels and indirectly to calcium and potassium channels
[438]. As glutamate is an excitatory neurotransmitter in the
cell, depolarization of the membrane occurs. Glutamate binds
to the NMDA receptor and an influx of Ca2+ enters the
cell and causes a disruption in calcium homeostasis. This
disruption can eventually lead to cell death.
NO2 ∙ acts as an outdoor and indoor air pollutant from
car emissions, fossil fuels, cigarette smoke, heaters, and gas
stoves, just to name a few [439]. NO2 ∙ is primarily found
in the airways of the terminal bronchi; however, NO2 ∙ may
be found in other areas of the respiratory tract. Minimal
exposure to NO2 ∙ results in long morphological changes
resulting in possible inflammation, pulmonary edema, and
cellular injury [440]. Nitrogen dioxide exposure also leads
to an increase in TBARS, a marker for lipid peroxidation
in lung tissue, and vitamin E treatment showed a reduced
pulmonary injury [441]. NO2 ∙ serves as an oxidant in inflammation mediated by the peroxidases, eosinophil peroxidase,
and myeloperoxidase [442–446]. This gas can oxidize the
antioxidant glutathione and increase activity of glutathione
reductase and glutathione peroxidase [447, 448]. The depletion of glutathione shifts the balance to the side of nitrosative
stress. NO2 ∙ can also be formed by the oxidation of ONOO− ,
another potent reactive nitrogen species.

10. An Overview of Some
Neurodegenerative Diseases
Neurodegenerative diseases are a classification of disorders
in which neuronal loss and progressive cognitive decline are
observed. These two consequences contribute to the memory
loss exhibited by those with neurodegenerative disorders.
This level of decline is accelerated in contrast to the normal
aging process. Depending on the specific disease other
characteristics and symptoms include dementia, a decline
in motor function, and depression may be evident. The
phenomenon of oxidative stress has been well-established
in such neurodegenerative disorders as Huntington’s disease
[449, 450], Parkinson’s disease [451], amyotrophic lateral
sclerosis [452], and Alzheimer’s disease [453–455]. This section will only highlight the correlation between autophagy,
apoptosis, and oxidative stress in the following neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis.
10.1. Alzheimer’s Disease. Alzheimer’s disease (AD), the most
common form of dementia, is a neurodegenerative disease
currently affecting millions of people worldwide. Age is
one risk factor of AD, as the onset of disease typically
occurs at about 65 years old. Although AD is an age-related
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neurodegenerative disease, it can be inherited (familial AD)
and sporadic. Familial AD (FAD) is very rare, as it affects less
than 10% of those afflicted with the disease. There are four
distinct types of FAD caused by the genetic factors described
below [456–458]. Sporadic AD usually occurs in the late stage
of AD and is associated with apolipoprotein E4 (APOE4)
allele. Apolipoprotein E (APOE) helps transport cholesterol
into the bloodstream. APOE4 is also involved in learning and
memory as persons with the APOE4 allele showed a decline
in processing new information [459]. APOE4 shows an
increase of amyloid beta peptide and neurofibrillary tangles
(NFT) [460, 461]. Increased oxidative stress is prevalent in
AD and also linked to APOE4 [462, 463]. Ramassamy et al.
demonstrated that tissue from patients with the APOE4 allele
showed a decrease in activity of the antioxidant enzymes
glutathione peroxidase and catalase [463]. Other risk factors
include family history of disease, reduced brain volume,
traumatic brain injury, and low education and mental ability
early in life [464–468].
Extreme neurofibrillary tangles and senile plaques are the
hallmarks of AD. These NFT are composed of paired helical
filaments, which consist of hyperphosphorylated tau protein.
The senile plaques are composed of amyloid beta (A𝛽) peptide. Amyloid precursor protein (APP) is a transmembrane
protein that plays a role in neuronal plasticity, long term
potentiation, and memory loss [469]. APP is proteolytically
cleaved by the enzymes 𝛽-secretase and 𝛾-secretase to form a
40–42 amino acids’ peptide, amyloid beta (A𝛽) peptide. The
two major forms of A𝛽 found in human brain are A𝛽(1–40)
and A𝛽(1–42). A𝛽(1–42) is the more toxic form of A𝛽 and
is the primary component of the senile plaque [470, 471].
A𝛽(1–42) induces oxidative stress in vivo [472, 473] and in
vitro [474]. After this toxic peptide is formed, it can aggregate
and these aggregates can accumulate outside or inside the cell
contributing to the pathogenesis of AD.
There are three human causative genetic alterations in
AD (APP; PS1; and PS2) and several genes associated with
AD (APOE4, 𝛼-2 macroglobulin, chromosome 10, and chromosome 12). APP is a precursor to amyloid beta peptide.
There are several APP mutations (i.e., Artic, Flemish London,
Dutch, Italian, Indiana, Iranian, etc.) that cause AD by
many different mechanisms (i.e., protofibril formation, dense
senile plaques, and increased A𝛽(1–42) production) [457,
475–478]. The highly characterized Swedish mutant Tg2576
transgenic mouse model for Alzheimer’s disease contains
human APP and has A𝛽 plaques deposits as early as 9 months
old [479, 480], leading to increased memory decline with
age. Presenilin 1 (PS1) and presenilin 2 (PS2) are catalytic
components of 𝛾-secretase and are highly involved in APP
processing. Mutations in PS1 or PS2 show an increase in
A𝛽(1–42) production and are the cause of most FAD cases
[456, 481–484]. Mutations in APP, PS1, and PS2 have been
found in the first clinical stage of AD and MCI [485], early
stage AD (EAD) [486], and late stage AD [487]. The APP/PS1
mutant mouse is a common model for AD as it exhibits
early amyloid deposition and increased oxidative stress [488,
489]. A significant increase in levels of protein carbonyls,
4-hydroxynonenal, and 3-nitrotyrosine levels, markers of
oxidative stress, was exhibited in APP/PS1 double mutant
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neurons compared to wild type [489]. A triple transgenic
(3XTg-AD) mouse model has been recently used to study the
pathogenesis of Alzheimer disease. Similarly to the double
APP/PS1 mouse, the 3XTg-AD mouse model exhibits oxidative imbalance as antioxidant levels are reduced and lipid
peroxidation and overall brain oxidation are increased [490].
These mice have mutations in the PS1 gene and are
homozygous for the Swedish APP mutation and tau P301L
mutation, making them highly representative of this disorder
and an excellent model to use as amyloid deposition is
observed at 3 months, hippocampal hyperphosphorylated
tau appears at 12–15 months, and synaptic transmission is
impaired at an early age, making them ideal to study this
neurodegenerative disorder.
Chromosome 10 codes several particular genes of interest
as possible risk factors of AD [491]. Insulin degrading enzyme
(IDE) is one such gene. IDE degrades and clears A𝛽 in the
brain [492, 493]. IDE levels are reduced in hippocampus
[494] and this protein’s catalytic activity is lowered in AD as
well [495]. IDE, as the name infers, degrades insulin. Statin
drugs have been shown to promote astrocytic IDE secretion
in AD model to stimulate autophagy [496]. Abnormalities
in insulin metabolism are associated with APOE status. AD
patients with the APOE4 allele had higher insulin levels than
patients without E4 allele [497] Elevated plasma insulin levels
correlate to increased A𝛽 levels, which as previously mentioned has detrimental effects [498, 499]. Therefore, chromosome 10 mutations may be a possible risk factor in AD.
𝛼-2-Macroglobulin (𝛼2 M) is encoded by chromosome 12
and is thought to be a possible risk factor for AD as well [500].
𝛼2 M protein binds to A𝛽 and transports it from neurons into
cells for degradation using the LRP receptor [501]. APOE uses
this same receptor to enter into cells. Therefore, APOE4 or
excess APOE may prevent the A𝛽/𝛼2 M complex from binding to the receptor and clearing for the neuron. 𝛼2 M has been
shown to be neuroprotective against 𝛽 amyloid fibrils in vitro
[502] and in vivo [503] inhibiting toxicity. Mutations in this
protein may result in A𝛽 deposition and neuron death [504].
Microglial activation has been linked to A𝛽 plaques in
Alzheimer’s disease. This activation results in a neuroinflammation and phagocytic impairment [505]. This inflammatory
response leads to the release of TNF-𝛼 and interleukin-1𝛽
[506]. Once the A𝛽 peptide activates the microglia, nitric
oxide is released [413], thereby promoting an oxidative stress
via peroxynitrite elevation which can alter calcium homeostasis and promote cellular apoptosis [507].
10.2. Parkinson’s Disease. Parkinson disease (PD), the second
most prevalent age-dependent neurodegenerative disorder, is
classified as a tauopathy, a neurological disorder that exhibits
excessive levels of phosphorylated tau.
Tau is a microtubule-associated protein that is responsible for stabilizing microtubules. Microtubules are neuronresident, cylindrically shaped, dynamic structures composed
of alternating rows of 𝛼- and 𝛽-tubulin. Microtubules play a
pivotal role in facilitating intracellular transport by assisting
in motor protein-driven transport of vesicles, mitochondria,
and other cargos in neurons. If tau is damaged, it can
no longer stabilize these microtubules, thereby reducing
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transport of critical factors to the neuron due to cytoskeletal
disintegration. Ultimately, neurons become energy starved
leading to apoptosis. Parkinson’s disease is strongly correlated
with neuroinflammation which is demonstrated by activated
astrocytes and microglia in the central nervous system. The
activation of these glial cells is detrimental to neurons and
promotes neuronal loss.
Parkinson’s disease presents as a decline in motor function in the form of resting tremors, muscle rigidity, and
dyskinesia. This disease is attributed to protein aggregates of
𝛼-synuclein, a protein whose main function is mitochondrial
functionality, vesicle trafficking, and synaptic vesicle formation [508, 509]. Alpha synuclein is predominantly located
in the presynaptic terminals; thereby accumulation results
in poor neurotransmission. These aggregates are the major
component of Lewy bodies located primarily in the putamen
and substantia nigra of the brain. These two regions are
largely involved in motor movement and learning. Activated
microglia are found largely in the substantia nigra and
striatum of PD animals [510]. Oxidative stress in PD brain
is evident by DNA damage [511] and increased levels of
carbonylated proteins [512]. Neuronal dopamine, a key neurotransmitter involved in motor function, levels are significantly diminished in the substantia nigra causing substantial
neuronal death. Aggregation also leads to Complex I impairment in dopaminergic neurons [513]. Protein aggregation in
combination with dopamine loss causes a profound effect on
the physical capabilities of persons suffering from Parkinson
disease and late in the disease cognitive dysfunction is often
observed. Posttranslational nitration of alpha synuclein [514]
and Complex I [508] lead to altered energy metabolism which
is evident in neurodegenerative disorders that are associated
with oxidative stress.
The most commonly used models of PD include treatment with rotenone, 6-OHDA, or 1-methyl-4-phenyl-1,2,5,6tetrahydropyridine (MPTP) induction. As muscle rigidity
is a hallmark of PD, mitochondria are highly impacted by
this neurodegenerative disease. Both the Krebs cycle and
oxidative phosphorylation are the major energy generating
processes of the mitochondria. When combined, both processes yield approximately 40 ATP molecules, providing the
necessary energy for the body’s daily function. Rotenone is an
inhibitor to Complex I in the mitochondria, thereby reducing
the proton gradient and energy production of the cell.
Neurons treated with as little as 0.3 𝜇M of rotenone generated
superoxide radicals, thereby promoting oxidative stress [515].
1-Methyl-4-phenyl-4-propionoxy-piperidine
(MPPP)
and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)
have been shown to induce PD pathology [516]. Originally,
they were discovered in heroin patients who developed
Parkinsonian-like symptoms following use of a “synthetic
heroin” distributed in California in the 1980s. This synthetic
blend was a mixture of MPTP and MPPP. MPTP easily
crosses the blood-brain barrier and is taken up by astrocytes
and metabolized into 1-methyl-4-phenylpyridinium (MPP+ ),
which further breaks down into toxic compounds including
3,4-dihydroxyphenylacetaldehyde (DOPAL) [517], a compound that removes dopamine from synaptic vesicles. The
oxidized product, MPP+ , inhibits Complex I of the electron
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transport chain working in a similar mechanism as rotenone.
MPTP induces a slow progression of the nonmotor and
motor symptoms of PD, allowing for longitudinal studies
that demonstrate a realistic progression of PD. This is
preferred by PD researchers over other toxins such as 6-hydroxydopamine (6-OHDA) [517].
Recent research has investigated the use of gliptins to
prevent neuronal loss in animal models of Parkinson’s disease. Gliptins are peptides that prevent neurodegeneration
by preventing apoptosis and neuroinflammation by altering
GLP-1, a glucagon-like peptide-1. Abdelsalam has shown that
vildagliptin, a dipeptidyl peptidase, reduced iNOS, caspase-3,
and myeloperoxidase levels. The antioxidant potential of this
drug also blocked the RAGE/NFK-𝛽 cascade, thereby lessening neuroinflammation in the rodent rotenone Parkinsonian
model [518]. Additionally, activation of aldehyde dehydrogenase, a mitochondrial enzyme responsible for detoxification
of toxic aldehydes, has been shown to protect SH-SY5Y
cells against rotenone-induced apoptotic cell death, thereby
lowering oxidative stress levels [519]. Other studies involving
the upregulation of antioxidants to promote cell survival in
rotenone cell mediated toxicity and MPTP-induced Parkinson disease include ferulic acid (Ojha, DDT, 2015), catalase
[520], a sirtuin, SIRT5 [521], pyrroloquinoline quinone [522],
and the phenylpropanoid glycoside salidroside [523]. These
results are promising in the development of a potential
Parkinson’s disease strategy.
The neurotoxin 6-hydroxydopamine (6-OHDA) is also
capable of inducing Parkinson’s-like symptoms, and its use
in animal models of PD predates the discovery of MPTP’s
neurotoxic properties [524]. This destroys tyrosine hydroxylase (TH) containing neurons [517]. TH catalyzes the ratelimiting step for the production of dopamine, a pivotal neurotransmitter involved in motor functions. This neurotoxin
plays a key role in modifying the nigrostriatal pathway in
which dopaminergic neurons are produced.
Recently, Kostrzewa et al. have shown that early administration of 6-OHPA promotes a lifelong model for severe
Parkinson’s disease [525]. In this study, bilateral intracisternal or intracerebroventricular administration of 6-hydroxydopamine (6-OHDA) was given to perinatal rats. Elevated levels of hydroxyl radical and extreme loss of striatal dopaminergic neurons were observed. However, there
were no differences in lifespan, feeding behavior, or motor
function. This novel model promotes lifelong Parkinsonian
symptoms without the characteristic motor deficits observed
in PD, providing a truly unique system to study Parkinson’s disease progression. Other studies aimed at reducing the oxidative stress promoted by 6-OHDA induction
include the administration of antioxidants that also have
anti-inflammatory properties such as echinacoside [526],
PEG conjugated recombinant human FGF-2 [527], madopar
(a combination of the dopamine precursor, levodopa, and
benserazide, a decarboxylase inhibitor) [528], guanosine, an
MPP+ antagonist [529], and carnosine [530]. A safe, effective,
combinatorial therapy of GAD and AAV2 vector which
codes for the dopamine synthetic enzyme, aromatic-l-amino
decarboxylase (AADC), has yielded encouraging results in
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a small number of PD patients by improving motor performance [531, 532]. This drug is currently in Phase II clinical
trial testing. These treatment strategies bolster the theory
of oxidative stress as a contributor to neurodegeneration
observed in neurodegenerative diseases.
10.3. Amyotrophic Lateral Sclerosis. Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a
progressive neurodegenerative disorder in which all voluntary muscle movement is lost within 1–5 years after disease
diagnosis. This disorder rapidly progresses to death within
2–5 years after the first symptoms are observed. ALS has
two forms: sporadic or inherited (familial), with approximately 90% of all ALS cases classified as sporadic. Like
PD, motor neurons are greatly affected in ALS resulting in
muscle weakness, spasticity, and atrophy [533]. In the motor
cortex, cerebellum, and parietal cortex, both forms of ALS
display protein oxidation, DNA damage, and MDA modified
proteins. Patients suffering from sporadic ALS showed a
significant increase in these aforementioned oxidative insults
compared to familial ALS subjects, thereby supporting the
role of oxidative stress in amyotrophic lateral sclerosis [452].
Twenty percent of persons with inherited ALS have a mutation in the antioxidant enzyme superoxide dismutase, which
leads to cellular toxicity [534]. This mutation lowers the
ability to combat potentially harmful free radicals, thereby
increasing levels of oxidative stress [535]. Mutant SOD1 can
aggregate in the cytoplasm in motor neurons of inherited
ALS patients and in various mouse models. These aggregates
are capable of inducing apoptosis in cortical neurons of the
G93A-SOD1 mouse, which has been widely studied as it has
pathology similar to that of ALS. In the G93A-SOD1 mouse
model, Ala for Gly substitution occurs at position 93. This
transgenic mouse overexpresses mutant human SOD1 and
exhibits the age-dependent motor neuronal characteristics
associated with amyotrophic lateral sclerosis. In familial
ALS patients with SOD1 mutations, a significant increase
in oxidative stress, as indexed by protein carbonyls, was
observed compared to control subjects [536].
It has been speculated that autophagy may play a direct
role in neurodegeneration via this glutamate mechanism.
This prevents the accumulation of proteins thereby reducing
the risk of several neurodegenerative disorders including
Alzheimer’s disease (accumulation of A𝛽), Parkinson’s disease (accumulation of alpha synuclein), and Huntington’s
disease (accumulation of the huntingtin protein). Interestingly, Manchon has shown that the huntingtin protein is
degraded by sphingosine kinase 1 in the sphingosine-1phosphate pathway to promote cell survival via autophagy
[537]. These results show a novel target for treatment of
neurodegenerative disease. Defects in this process have been
strongly associated with neurodegeneration [538, 539].
As ALS is a motor neuron disorder, the motor neurons
of the central nervous system are greatly affected. Rojas
et al. have shown that, in astrocytes of conditioned media
that express human SOD1 in the G93A mouse model, c-Abl
was activated [540]. This activation also caused opening of
the mitochondrial permeability transition pore. C-Abl is a
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tyrosine kinase that promotes apoptosis and ROS generation.
Administration of the antioxidants trolox, esculetin, and
tiron prevented c-Abl activation, thereby reducing oxidative
stress and neuronal loss. In cell culture, it has been demonstrated that cells from the spinal cords of G93A mice overexpress transcription factor EB, which regulates autophagy. The
expression of beclin-1 and LC3-II, both crucial autophagic
markers, was observed as well in this study [541].
10.4. Mitochondrial Effect. Mitochondria are the powerhouse
of ATP production in the cell. Mitochondria travel on
microtubules with assistance of motor proteins (kinesin and
dynein) to the presynaptic terminal and return to the soma.
Mitochondrial dysfunction is a classic event observed in neurodegeneration as increased oxidative stress has deleterious
effects on the mitochondria. Reduced energy metabolism
has been observed in most neurodegenerative disorders.
Dysregulation of mitochondria may also lead to alterations
in the mitochondrial membrane potential which is an early
characteristic of apoptosis. One leading theory to prevent
neurodegeneration is reversing mitochondrial dysfunction.
Several antioxidant therapies have been strategically targeted
to the mitochondria to support this notion. Coenzyme Q10
(CoQ10 ) plays a key role in oxidative phosphorylation and
has neuroprotective properties. It has been widely investigated in the treatment of neurodegenerative disorders [542,
543]. This quinone delays functional decline but does not
increase dopamine levels. Although coenzyme Q10 has shown
promising results, its transport across the blood-brain barrier
is poor. A new family of mitochondrial antioxidants, the
Szeto-Schiller (SS) peptides, have shown an increase in
motor function and cell survival [544]. These antioxidants
have also protected dopaminergic neurons against MPTP
neurotoxicity, thereby reducing effects of Parkinson’s disease
and stimulating the field of Parkinson’s disease research.
Another avenue of treatment includes stimulation of the high
mobility group box 1 protein (HMGB-1). The high mobility
group box 1 protein is a chromatin binding protein that
recognizes DNA damage and promotes binding to p53 to
stimulate an oxidative stress response, namely, autophagy or
apoptosis. Studies investigating the correlation of HMGB1 and mitochondrial dysfunction in 3-nitropropionic acid
treated animals have been conducted to study the role
HGMB-1 may have on striatal neurodegeneration in vivo
and in vitro [545]. They demonstrated that HMGB-1 binds
to beclin-1 to regulate autophagy, thereby establishing a
new mechanism to study in striatal neurodegeneration via
autophagy and apoptosis.
Oxidative stress is a well-established phenomenon that
occurs in neurodegenerative disease. This coupled with an
increase in apoptosis and autophagy contributes to the neurodegeneration and memory loss observed in Alzheimer’s
disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Reactive oxygen and nitrogen species are highly abundant
in these disorders as well. New antioxidant and mitochondrial
based therapies show promise to reduce neuronal cell loss and
promote neuroprotection, which will have a positive effect on
patient outcomes.
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11. Conclusions
In the whole, available data indicate that mitochondria are
a significant source of ROS, but evidence for or against
mitochondria being the main source of cellular ROS is
lacking. However, there is convincing evidence that increases
in mitochondrial ROS production can lead to mitochondrial
and cellular oxidative stress and dysfunction, even though
the same ROS can trigger mechanisms of tissue protection
against excessive oxidative stress. Less information is available on role played by other cellular ROS sources in these
processes. However, accumulating evidence favors the idea
that, in many cells and conditions, such sources play a role in
cellular oxidative damage as well as in survival mechanisms
activated by oxidative stress, contributing to tissue rescue
from excessive damage and dysfunction.
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[42] M. Löffler, C. Becker, E. Wegerle, and G. Schuster, “Catalytic
enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in
mammalian tissues, cells and mitochondria,” Histochemistry
and Cell Biology, vol. 105, no. 2, pp. 119–128, 1996.

Oxidative Medicine and Cellular Longevity
[43] L. Zhang, L. Yu, and C.-A. Yu, “Generation of superoxide anion
by succinate-cytochrome c reductase from bovine heart mitochondria,” The Journal of Biological Chemistry, vol. 273, no. 51,
pp. 33972–33976, 1998.
[44] A. A. Starkov, G. Fiskum, C. Chinopoulos et al., “Mitochondrial 𝛼-ketoglutarate dehydrogenase complex generates reactive
oxygen species,” The Journal of Neuroscience, vol. 24, no. 36, pp.
7779–7788, 2004.
[45] C. De Duve and P. Baudhuin, “Peroxisomes (microbodies and
related particles),” Physiological Reviews, vol. 46, no. 2, pp. 323–
357, 1966.
[46] M. Fransen, “Peroxisome dynamics: molecular players, mechanisms, and (Dys)functions,” ISRN Cell Biology, vol. 2012, Article
ID 714192, 24 pages, 2012.
[47] I. Singh, “Biochemistry of peroxisomes in health and disease,”
Molecular and Cellular Biochemistry, vol. 167, no. 1-2, pp. 1–29,
1997.
[48] V. D. Antonenkov, S. Grunau, S. Ohlmeier, and J. K. Hiltunen,
“Peroxisomes are oxidative organelles,” Antioxidants and Redox
Signaling, vol. 13, no. 4, pp. 525–537, 2010.
[49] A. Rokka, V. D. Antonenkov, R. Soininen et al., “Pxmp2 is
a channel-forming protein in mammalian peroxisomal membrane,” PLoS ONE, vol. 4, no. 4, Article ID e5090, 2009.
[50] R. Fritz, J. Bol, U. Hebling et al., “Compartment-dependent
management of H2 O2 by peroxisomes,” Free Radical Biology and
Medicine, vol. 42, no. 7, pp. 1119–1129, 2007.
[51] S. Angermüller, G. Bruder, A. Völkl, H. Wesch, and H. D.
Fahimi, “Localization of xanthine oxidase in crystalline cores of
peroxisomes. A cytochemical and biochemical study,” European
Journal of Cell Biology, vol. 45, no. 1, pp. 137–144, 1987.
[52] D. B. Stolz, R. Zamora, Y. Vodovotz et al., “Peroxisomal localization of inducible nitric oxide synthase in hepatocytes,”
Hepatology, vol. 36, no. 1, pp. 81–93, 2002.
[53] J. Groenendyk and M. Michalak, “Endoplasmic reticulum
quality control and apoptosis,” Acta Biochimica Polonica, vol. 52,
no. 2, pp. 381–395, 2005.
[54] G. L. E. Koch, “The endoplasmic reticulum and calcium storage,” BioEssays, vol. 12, no. 11, pp. 527–531, 1990.
[55] A. E. Crib, M. Peyrou, S. Muruganandan, and L. Schneider, “The
endoplasmic reticulum in xenobiotic toxicity,” Drug Metabolism
Reviews, vol. 37, no. 3, pp. 405–442, 2005.
[56] J. R. Gillette, B. B. Brodie, and B. N. La Du, “The oxidation of
drugs by liver microsomes: on the role of TPNH and oxygen,”
The Journal of Pharmacology and Experimental Therapeutics,
vol. 119, no. 4, pp. 532–540, 1957.
[57] R. W. Estabrook, S. Kawano, J. Werringloer et al., “Oxycytochrome P-450: its breakdown to superoxide for the formation
of hydrogen peroxide,” Acta Biologica et Medica Germanica, vol.
38, no. 2-3, pp. 423–434, 1979.
[58] H. Kuthan and V. Ullrich, “Oxidase and oxygenase function
of the microsomal cytochrome P450 monooxygenase system,”
European Journal of Biochemistry, vol. 126, no. 3, pp. 583–588,
1982.
[59] E. R. Stadtman, “Oxidation of proteins by mixed-function oxidation systems: implication in protein turnover, ageing and
neutrophil function,” Trends in Biochemical Sciences, vol. 11, no.
1, pp. 11–12, 1986.
[60] P. S. Aguilar and D. de Mendoza, “Control of fatty acid desaturation: a mechanism conserved from bacteria to humans,”
Molecular Microbiology, vol. 62, no. 6, pp. 1507–1514, 2006.

Oxidative Medicine and Cellular Longevity
[61] M. A. Thiede, J. Ozols, and P. Strittmatter, “Construction and
sequence of cDNA for rat liver stearyl coenzyme A desaturase,”
The Journal of Biological Chemistry, vol. 261, no. 28, pp. 13230–
13235, 1986.
[62] J. A. Napier, L. V. Michaelson, and O. Sayanova, “The role of
cytochrome b5 fusion desaturases in the synthesis of polyunsaturated fatty acids,” Prostaglandins Leukotrienes and Essential
Fatty Acids, vol. 68, no. 2, pp. 135–143, 2003.
[63] A. G. Mitchell and C. E. Martin, “A novel cytochrome b5-like
domain is linked to the carboxyl terminus of the Saccharomyces
cerevisiaeΔ-9 fatty acid desaturase,” The Journal of Biological
Chemistry, vol. 270, no. 50, pp. 29766–29772, 1995.
[64] J. B. Schenkman and I. Jansson, “The many roles of cytochrome
b5,” Pharmacology & Therapeutics, vol. 97, no. 2, pp. 139–152,
2003.
[65] A. K. Samhan-Arias and C. Gutierrez-Merino, “Purified
NADH-cytochrome b5 reductase is a novel superoxide anion
source inhibited by apocynin: sensitivity to nitric oxide and
peroxynitrite,” Free Radical Biology and Medicine, vol. 73, pp.
174–189, 2014.
[66] C. Hwang, A. J. Sinskey, and H. F. Lodish, “Oxidized redox state
of glutathione in the endoplasmic reticulum,” Science, vol. 257,
no. 5076, pp. 1496–1502, 1992.
[67] A. R. Frand and C. A. Kaiser, “Ero1p oxidizes protein disulfide
isomerase in a pathway for disulfide bond formation in the
endoplasmic reticulum,” Molecular Cell, vol. 4, no. 4, pp. 469–
477, 1999.
[68] B. P. Tu and J. S. Weissman, “The FAD- and O2 -dependent
reaction cycle of Ero1-mediated oxidative protein folding in the
endoplasmic reticulum,” Molecular Cell, vol. 10, no. 5, pp. 983–
994, 2002.
[69] B. P. Tu and J. S. Weissman, “Oxidative protein folding in
eukaryotes: mechanisms and consequences,” The Journal of Cell
Biology, vol. 164, no. 3, pp. 341–346, 2004.
[70] V. P. Skulachev, “Why are mitochondria involved in apoptosis?
Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and
cell,” FEBS Letters, vol. 397, no. 1, pp. 7–10, 1996.
[71] K.-J. Cho, J.-M. Seo, and J.-H. Kim, “Bioactive lipoxygenase
metabolites stimulation of NADPH oxidases and reactive oxygen species,” Molecules and Cells, vol. 32, no. 1, pp. 1–5, 2011.
[72] B. M. Babior, “NADPH oxidase: an update,” Blood, vol. 93, no.
5, pp. 1464–1476, 1999.
[73] S. J. Chanock, J. El Benna, R. M. Smith, and B. M. Babior, “The
respiratory burst oxidase,” The Journal of Biological Chemistry,
vol. 269, no. 40, pp. 24519–24522, 1994.
[74] Y.-A. Suh, R. S. Arnold, B. Lassegue et al., “Cell transformation
by the superoxide-generating oxidase Mox1,” Nature, vol. 401,
no. 6748, pp. 79–82, 1999.
[75] M. Katsuyama, “NOX/NADPH oxidase, the superoxide-generating enzyme: its transcriptional regulation and physiological
roles,” Journal of Pharmacological Sciences, vol. 114, no. 2, pp.
134–146, 2010.
[76] C. Kim and M. C. Dinauer, “Impaired NADPH oxidase activity
in Rac2-deficient murine neutrophils does not result from
defective translocation of p47phox and p67 phox and can
be rescued by exogenous arachidonic acid,” The Journal of
Leukocyte Biology, vol. 79, no. 1, pp. 223–234, 2006.
[77] S. V. K. Mahipal, J. Subhashini, M. C. Reddy et al., “Effect of
15-lipoxygenase metabolites, 15-(S)-HPETE and 15-(S)-HETE
on chronic myelogenous leukemia cell line K-562: reactive

29

[78]

[79]

[80]

[81]

[82]

[83]

[84]
[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

oxygen species (ROS) mediate caspase-dependent apoptosis,”
Biochemical Pharmacology, vol. 74, no. 2, pp. 202–214, 2007.
H.-Y. Hong, W.-K. Jeon, and B.-C. Kim, “Up-regulation of heme
oxygenase-1 expression through the Rac1/NADPH oxidase/
ROS/p38 signaling cascade mediates the anti-inflammatory
effect of 15-deoxy-Δ12,14-prostaglandin J2 in murine macrophages,” FEBS Letters, vol. 582, no. 6, pp. 861–868, 2008.
G.-H. Sun-Wada, Y. Wada, and M. Futai, “Lysosome and lysosome-related organelles responsible for specialized functions
in higher organisms, with special emphasis on vacuolar-type
proton ATPase,” Cell Structure and Function, vol. 28, no. 5, pp.
455–463, 2003.
K. Arai, T. Kanaseki, and S. Ohkuma, “Isolation of highly purified lysosomes from rat liver: identification of electron carrier
components on lysosomal membranes,” Journal of Biochemistry,
vol. 110, no. 4, pp. 541–547, 1991.
L. Gille and H. Nohl, “The existence of a lysosomal redox
chain and the role of ubiquinone,” Archives of Biochemistry and
Biophysics, vol. 375, no. 2, pp. 347–354, 2000.
H. Nohl and L. Gille, “The bifunctional activity of ubiquinone in
lysosomal membranes,” Biogerontology, vol. 3, no. 1-2, pp. 125–
131, 2002.
B. Mayer and B. Hemmens, “Biosynthesis and action of nitric
oxide in mammalian cells,” Trends in Biochemical Sciences, vol.
22, no. 12, pp. 477–481, 1997.
C. Nathan and Q.-W. Xie, “Nitric oxide synthases: roles, tolls,
and controls,” Cell, vol. 78, no. 6, pp. 915–918, 1994.
O. Feron, L. Belhassen, L. Kobzik, T. W. Smith, R. A. Kelly, and T.
Michel, “Endothelial nitric oxide synthase targeting to caveolae.
Specific interactions with caveolin isoforms in cardiac myocytes
and endothelial cells,” The Journal of Biological Chemistry, vol.
271, no. 37, pp. 22810–22814, 1996.
F. A. Sánchez, N. B. Savalia, R. G. Durán, B. K. Lal, M. P.
Boric, and W. N. Durán, “Functional significance of differential
eNOS translocation,” American Journal of Physiology-Heart and
Circulatory Physiology, vol. 291, no. 3, pp. H1058–H1064, 2006.
P. A. Loughran, D. B. Stolz, Y. Vodovotz, S. C. Watkins, R. L.
Simmons, and T. R. Billiar, “Monomeric inducible nitric oxide
synthase localizes to peroxisomes in hepatocytes,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 102, no. 39, pp. 13837–13842, 2005.
M. S. Parihar, R. R. Nazarewicz, E. Kincaid, U. Bringold,
and P. Ghafourifar, “Association of mitochondrial nitric oxide
synthase activity with respiratory chain complex I,” Biochemical
and Biophysical Research Communications, vol. 366, no. 1, pp.
23–28, 2008.
N. Paolocc, U. E. G. Ekelund, T. Isoda et al., “cGMP-independent inotropic effects of nitric oxide and peroxynitrite
donors: potential role for nitrosylation,” American Journal of
Physiology—Heart and Circulatory Physiology, vol. 279, no. 4,
pp. H1982–H1988, 2000.
M. W. J. Cleeter, J. M. Cooper, V. M. Darley-Usmar, S. Moncada,
and A. H. V. Schapira, “Reversible inhibition of cytochrome c
oxidase, the terminal enzyme of the mitochondrial respiratory
chain, by nitric oxide. Implications for neurodegenerative
diseases,” FEBS Letters, vol. 345, no. 1, pp. 50–54, 1994.
J. J. Poderoso, J. G. Peralta, C. L. Lisdero et al., “Nitric oxide
regulates oxygen uptake and hydrogen peroxide release by the
isolated beating rat heart,” American Journal of Physiology—Cell
Physiology, vol. 274, no. 1, pp. C112–C119, 1998.
D. I. Simon, M. E. Mullins, L. Jia, B. Gaston, D. J. Singel,
and J. S. Stamler, “Polynitrosylated proteins: characterization,

30

Oxidative Medicine and Cellular Longevity
bioactivity, and functional consequences,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 93, no. 10, pp. 4736–4741, 1996.

[93] V. Borutaite, A. Budriunaite, and G. C. Brown, “Reversal of
nitric oxide-, peroxynitrite- and S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity by light
and thiols,” Biochimica et Biophysica Acta—Bioenergetics, vol.
1459, no. 2-3, pp. 405–412, 2000.
[94] R. Radi, A. Cassina, R. Hodara, C. Quijano, and L. Castro, “Peroxynitrite reactions and formation in mitochondria,” Free
Radical Biology and Medicine, vol. 33, no. 11, pp. 1451–1464, 2002.
[95] K. A. Lukyanov and V. V. Belousov, “Genetically encoded fluorescent redox sensors,” Biochimica et Biophysica Acta—General
Subjects, vol. 1840, no. 2, pp. 745–756, 2014.
[96] D. J. Hearse, “Reperfusion of the ischemic myocardium,” Journal of Molecular and Cellular Cardiology, vol. 9, no. 8, pp. 605–
616, 1977.
[97] M. L. Hess and N. H. Manson, “Molecular oxygen: friend and
foe. The role of the oxygen free radical system in the calcium
paradox, the oxygen paradox and ischemia/reperfusion injury,”
Journal of Molecular and Cellular Cardiology, vol. 16, no. 11, pp.
969–985, 1984.
[98] J. M. McCord, “Oxygen-derived free radicals in postischemic
tissue injury,” The New England Journal of Medicine, vol. 312, no.
3, pp. 159–163, 1985.
[99] J. S. Beckman, T. W. Beckman, J. Chen, P. A. Marshall, and
B. A. Freeman, “Apparent hydroxyl radical production by
peroxynitrite: implications for endothelial injury from nitric
oxide and superoxide,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 87, no. 4, pp. 1620–
1624, 1990.
[100] V. Braunersreuther, F. Montecucco, M. Asrih et al., “Role
of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in
myocardial ischemia/reperfusion injury,” Journal of Molecular
and Cellular Cardiology, vol. 64, pp. 99–107, 2013.
[101] H. Otani, H. Tanaka, T. Inoue et al., “In vitro study on contribution of oxidative metabolism of isolated rabbit heart
mitochondria to myocardial reperfusion injury,” Circulation
Research, vol. 55, no. 2, pp. 168–175, 1984.
[102] G. Ambrosio, J. L. Zweier, C. Duilio et al., “Evidence that
mitochondrial respiration is a source of potentially toxic oxygen
free radicals in intact rabbit hearts subjected to ischemia and
reflow,” The Journal of Biological Chemistry, vol. 268, no. 25, pp.
18532–18541, 1993.
[103] A. P. Halestrap, E. J. Griffiths, and C. P. Connern, “Mitochondrial calcium handling and oxidative stress,” Biochemical Society
Transactions, vol. 21, no. 2, pp. 353–358, 1993.
[104] J. J. Kane, M. L. Murphy, J. K. Bisset, N. deSoyza, J. E.
Doherty, and K. D. Straub, “Mitochondrial function, oxygen
extraction, epicardial S-T segment changes and tritiated digoxin
distribution after reperfusion of ischemic myocardium,” The
American Journal of Cardiology, vol. 36, no. 2, pp. 218–224, 1975.
[105] P. Venditti, P. Masullo, and S. Di Meo, “Effects of myocardial ischemia and reperfusion on mitochondrial function and
susceptibility to oxidative stress,” Cellular and Molecular Life
Sciences, vol. 58, no. 10, pp. 1528–1537, 2001.
[106] P. S. Brookes, S. B. Digerness, D. A. Parks, and V. Darley-Usmar,
“Mitochondrial function in response to cardiac ischemiareperfusion after oral treatment with quercetin,” Free Radical
Biology and Medicine, vol. 32, no. 11, pp. 1220–1228, 2002.

[107] P. Liu, C. E. Hock, R. Nagele, and P. Y.-K. Wong, “Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats,” American Journal of
Physiology—Heart and Circulatory Physiology, vol. 272, no. 5,
pp. H2327–H2336, 1997.
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[168] B. Lassègue, A. San Martı́n, and K. K. Griendling, “Biochemistry, physiology, and pathophysiology of NADPH oxidases in
the cardiovascular system,” Circulation Research, vol. 110, no. 10,
pp. 1364–1390, 2012.
[169] V. Braunersreuther, F. Montecucco, M. Asrih et al., “Role
of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in
myocardial ischemia/reperfusion injury,” Journal of Molecular
and Cellular Cardiology, vol. 64, pp. 99–107, 2013.
[170] A. Daiber, “Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species,”
Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1797,
no. 6-7, pp. 897–906, 2010.
[171] W.-G. Li, F. J. Miller Jr., H. J. Zhang, D. R. Spitz, L. W. Oberley,
and N. L. Weintraub, “H2 O2 -induced O2 —production by a nonphagocytic NAD(P)H Oxidase Causes Oxidant Injury,” The
Journal of Biological Chemistry, vol. 276, no. 31, pp. 29251–29256,
2001.
[172] J. S. McNally, A. Saxena, H. Cai, S. Dikalov, and D. G. Harrison,
“Regulation of xanthine oxidoreductase protein expression by
hydrogen peroxide and calcium,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 25, no. 8, pp. 1623–1628, 2005.
[173] J. S. McNally, M. E. Davis, D. P. Giddens et al., “Role of xanthine
oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress,” American

Oxidative Medicine and Cellular Longevity

[174]

[175]

[176]

[177]

[178]

[179]

[180]

[181]

[182]

[183]

[184]

[185]

[186]

[187]

[188]

[189]

[190]

Journal of Physiology—Heart and Circulatory Physiology, vol.
285, no. 6, pp. H2290–H2297, 2003.
B. Kaltschmidt, T. Sparna, and C. Kaltschmidt, “Activation of
NF-𝜅B by reactive oxygen intermediates in the nervous system,”
Antioxidants & Redox Signaling, vol. 1, no. 2, pp. 129–144, 1999.
R. E. Shackelford, W. K. Kaufmann, and R. S. Paules, “Oxidative
stress and cell cycle checkpoint function,” Free Radical Biology
and Medicine, vol. 28, no. 9, pp. 1387–1404, 2000.
C. K. Sen, “Cellular thiols and redox-regulated signal transduction,” Current Topics in Cellular Regulation, vol. 36, no. C, pp.
1–30, 2001.
M. S. Wolin, “Interactions of oxidants with vascular signaling
systems,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
20, no. 6, pp. 1430–1442, 2000.
F. A. Kuehl Jr. and R. W. Egan, “Prostaglandins, arachidonic
acid, and inflammation,” Science, vol. 210, no. 4473, pp. 978–984,
1980.
O. D. Saugstad, “Update on oxygen radical disease in neonatology,” Current Opinion in Obstetrics and Gynecology, vol. 13, no.
2, pp. 147–153, 2001.
M. Benhar, D. Engelberg, and A. Levitzki, “ROS, stressactivated kinases and stress signaling in cancer,” EMBO Reports,
vol. 3, no. 5, pp. 420–425, 2002.
J. G. Scandalios, “Oxidative stress: molecular perception and
transduction of signals triggering antioxidant gene defenses,”
Brazilian Journal of Medical and Biological Research, vol. 38, no.
7, pp. 995–1014, 2005.
V. J. Thannickal and B. L. Fanburg, “Reactive oxygen species in
cell signaling,” American Journal of Physiology—Lung Cellular
and Molecular Physiology, vol. 279, no. 6, pp. L1005–L1028, 2000.
G. Roos and J. Messens, “Protein sulfenic acid formation: from
cellular damage to redox regulation,” Free Radical Biology and
Medicine, vol. 51, no. 2, pp. 314–326, 2011.
S. Singh, S. Vrishni, B. K. Singh, I. Rahman, and P. Kakkar,
“Nrf2-ARE stress response mechanism: a control point in
oxidative stress-mediated dysfunctions and chronic inflammatory diseases,” Free Radical Research, vol. 44, no. 11, pp. 1267–
1288, 2010.
D. D. Zhang and M. Hannink, “Distinct cysteine residues in
Keap1 are required for Keap1-dependent ubiquitination of Nrf2
and for stabilization of Nrf2 by chemopreventive agents and
oxidative stress,” Molecular and Cellular Biology, vol. 23, no. 22,
pp. 8137–8151, 2003.
P. D. Ray, B.-W. Huang, and Y. Tsuji, “Reactive oxygen species
(ROS) homeostasis and redox regulation in cellular signaling,”
Cellular Signalling, vol. 24, no. 5, pp. 981–990, 2012.
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[426] J. Sastre, F. V. Pallardó, J. G. de la Asunción, and J. Viña, “Mitochondria, oxidative stress and aging,” Free Radical Research, vol.
32, no. 3, pp. 189–198, 2000.
[427] C. E. Thomas and S. D. Aust, “Free radicals and environmental
toxins,” Annals of Emergency Medicine, vol. 15, no. 9, pp. 1075–
1083, 1986.
[428] E. Niki, “Free radicals in the 1900’s: from in vitro to in vivo,” Free
Radical Research, vol. 33, no. 6, pp. 693–704, 2000.
[429] H. Schempp, E. Albrecht-Goepfert, and E. F. Elstner, “Detection
of the production of reactive oxygen species by neutrophils in
whole blood: modulation by adamantanes and triggering by
Fe3+ -ions,” Zeitschrift für Naturforschung, vol. 54, no. 7-8, pp.
562–568, 1999.
[430] B. S. van der, M. P. Veen, and P. Heeringa, “Myeloperoxidase:
molecular mechanisms of action and their relevance to human
health and disease,” Antioxidants & Redox Signaling, vol. 11, pp.
2899–2937, 2009.
[431] M. Whiteman, J. P. E. Spencer, A. Jenner, and B. Halliwell,
“Hypochlorous acid-induced DNA base modification: potentiation by nitrite: biomarkers of DNA damage by reactive oxygen
species,” Biochemical and Biophysical Research Communications, vol. 257, no. 2, pp. 572–576, 1999.
[432] M. Saran, I. Beck-Speier, B. Fellerhoff, and G. Bauer, “Phagocytic killing of microorganisms by radical processes: consequences of the reaction of hydroxyl radicals with chloride
yielding chlorine atoms,” Free Radical Biology and Medicine, vol.
26, no. 3-4, pp. 482–490, 1999.
[433] K. Eto, T. Asada, K. Arima, T. Makifuchi, and H. Kimura, “Brain
hydrogen sulfide is severely decreased in Alzheimer’s disease,”
Biochemical and Biophysical Research Communications, vol. 293,
no. 5, pp. 1485–1488, 2002.
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and L. Boscá, “Protein kinase C𝜀 is required for macrophage
activation and defense against bacterial infection,” The Journal
of Experimental Medicine, vol. 194, no. 9, pp. 1231–1242, 2001.
[438] L. Fagni and J. Bockaert, “Effects of nitric oxide on glutamategated channels and other ionic channels,” Journal of Chemical
Neuroanatomy, vol. 10, no. 3-4, pp. 231–240, 1996.
[439] R. L. Persinger, M. E. Poynter, K. Ckless, and Y. M. W. Janssen-Heininger, “Molecular mechanisms of nitrogen dioxide
induced epithelial injury in the lung,” Molecular and Cellular
Biochemistry, vol. 234-235, pp. 71–80, 2002.
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